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A clinical and molecular analysis of Clostridium difficile isolated from symptomatic patients 
at Groote Schuur Hospital was conducted in order to gain insight into the identity, 
epidemiology and pathogenesis of the various strains. C. difficile was detected and isolated 
by selective culture from stool specimens from 34 of the 162 symptomatic patients (20%). 
Three toxigenic-types were distinguished by PCR: A+B+ (47%), A-B+ (47%) and A-B- 
(6%), none of which harboured the binary toxin genes. Compared to the direct culture 
method, enzyme immunoassay-based detection tests (Meridian ImmunoCard and bioMérieux 
MiniVidas) were found to be lacking clinical sensitivity, while nucleic acid amplification 
tests (Hain Lifescience CDiff and Cepheid GeneXpert) were far more sensitive in the local 
clinical setting. PCR ribotyping identified all the A-B+ strains as PCR ribotype 017, which 
was the prevalent strain type (47%). Genotyping based on the tcdC gene and MLVA both 
grouped the ribotype 017 strains in a single clade. The antimicrobial susceptibility of all the 
isolates to metronidazole (MET), vancomycin (VAN), moxifloxacin (MOX) and 
erythromycin (ERY) were determined by the Etest method. All were sensitive to MET and 
VAN; however, four ribotype 017 strains displayed reduced susceptibility to MET. With 
regard to MOX, reduced susceptibly and full resistance were observed in 32% and 12% of the 
isolates, respectively, with all of these belonging to ribotype 017. MOX-resistant strains had a 
Thr82Ile amino acid substitution in the GyrA enzyme and strains displaying reduced 
susceptibility to MOX had an Asp426Asn amino acid substitution in GyrB. High-level 
resistance to ERY was observed in 47% of the isolates, which were primarily ribotype 017. 
ERY-resistant strains all harboured the ermB gene, suggesting that this was the genetic basis 
of the observed phenotype. Auto-aggregation analysis revealed that the ribotype 017 strains 
were significantly stronger auto-aggregators than the other ribotypes examined. Results of 
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semi-quantitative RT-PCR analysis suggest that the expression level of the cwpV gene, 
encoding the CwpV protein, may play a role in auto-aggregation. In conclusion, this pilot 
study revealed that the GeneXpert method was the most accurate and sensitive technique for 
diagnosing CDI in the clinical setting at Groote Schuur Hospital. Ribotype 017 was the most 
prevalent strain type, and the antimicrobial resistance profile and increased auto-aggregation 
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Clostridium difficile is a Gram positive, anaerobic bacterium, which has emerged as the 
leading cause of healthcare- and antimicrobial-associated diarrhoeas. Disease symptoms 
range from mild diarrhoea to potentially fatal pseudomembranous colitis and are collectively 
known as Clostridium difficile infection (CDI) or C. difficile-associated disease (CDAD). 
CDI caused by various C. difficile strains has reached epidemic proportions in hospitals 
worldwide and numerous studies have been conducted in order to characterise this pathogenic 
bacterium and to understand its ability to persist and cause disease. The pathogenesis and the 
epidemiology of C. difficile, as well as the diagnosis and treatment of CDI, the typing of C. 




1.2.1 Risk factors in the development of CDI 
Antimicrobials 
Antimicrobial therapy is the primary risk factor for developing CDI (Baxter et al., 2008; 
Spigaglia et al., 2011). Antimicrobial use disturbs the normal enteric microbiota and selects 
for the growth of C. difficile (De La Cochetière et al., 2008; Sullivan et al., 2001). C. difficile 
spores and/or vegetative cells can remain, in low numbers, as a part of the enteric microbiota 
in asymptomatic individuals (Kyne et al., 2000). However, there is a difference in the 
abundance and diversity of the microbiota between asymptomatic and healthy individuals 
(Zhang et al., 2015). Disruption of the microbiota and mucosa provides C. difficile with the 
opportunity to proliferate and colonise (Pérez-Cobas et al., 2014). In addition, antimicrobials 
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have been shown to promote bacterial growth and toxin production by resistant epidemic-
associated C. difficile strains (Adams et al., 2007; Freeman et al., 2007).  
Broad-spectrum antimicrobials such as penicillins, clindamycin, fluoroquinolones and 
cephalosporins are commonly administered in hospital environments and have been 
associated with the development of CDI and associated outbreaks (Biller et al., 2007; 
Dubberke et al., 2015; Johnson et al., 1999; Pépin et al., 2005). In the 1970’s, clindamycin 
was considered the highest-risk antimicrobial to cause CDI (Tedesco et al., 1974). Thereafter, 
the decreased use of clindamycin in hospitals in Europe and the USA led to fewer cases of 
CDI (Climo et al., 1998; Pear et al., 1994). Clindamycin use is still suggested as a potential 
risk factor for CDI caused by A-B+ strains of C. difficile (Kim et al., 2012a; Kuijper et al., 
2001) (see section 1.2.3). During the 1980’s and 1990’s, the use of cephalosporins, such as 
cefuroxime, ceftriaxone and cefotaxime, was identified as a risk factor for CDI acquisition 
(de Lalla et al., 1989; Nelson et al., 1994). Reducing the use of cephalosporins has been 
shown to reduce the incidence of CDI (Thomas & Riley, 2003). In addition, fluoroquinolones 
have been identified as a potential risk factor for developing CDI (Pépin et al., 2005). 
Other risk factors 
Immunosuppression as the result of old age, autoimmune disease and immune deficiency is a 
risk factor for CDI due to the disruption of the enteric microbiota associated with these 
conditions (Kyne et al., 2000, 2001, 2002). The pathophysiology of the intestine associated 
with Hirschsprung’s Disease and inflammatory bowel disease are also risk factors for 
developing CDI (Rodemann et al., 2007; Schechter et al., 1999). Another contributing risk 
factor is mucosal damage of the intestine by chemotherapy, radiation and gastrointestinal 
surgery (Hautmann et al., 2011; Husain et al., 1998; Zerey et al., 2007). 
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Some studies suggest that the use of proton pump inhibitors (PPI) that suppress gastric acidity 
can increase the risk of CDI (Aseeri et al., 2008; Dial et al., 2004). However, this is disputed 
with some other studies having described a lack of association between PPI and CDI 
(Freedberg et al., 2013). 
1.2.2 The role of C. difficile toxins in pathogenesis 
Large clostridial toxins A and B 
The diseases caused by C. difficile are largely mediated by toxin A (TcdA) and toxin B 
(TcdB) (Just et al., 1995a, b). These toxins are glucosyltransferases that irreversibly 
inactivate host cell Rho GTPases using UDP-glucose as the donor (Jank & Aktories, 2008; 
Voth & Ballard, 2005). GTPases, such as Rho proteins are involved in the regulation of the 
cellular actin cytoskeleton and paracellular permeability at the tight junctions. Modification 
of these GTPases can result in cell apoptosis, degradation of the actin cytoskeleton or 
interruption in cell signalling of intoxicated cells. These modifications can induce 
inflammation and degrade the intestinal epithelial tissue, manifesting as diarrhoea and 
pseudomembranous colitis, the primary symptoms of CDI. 
Binary toxin 
An additional toxin, the binary toxin, contributes to the disease caused by C. difficile (Perelle 
et al., 1997). Two components make up the toxin. CdtA is the enzymatic component, which 
is an actin-modifying ADP-ribosyltransferase. CdtB is a separate component that binds to the 
targeted host cell and transports CdtA into the cell. Binary toxins stimulate the excessive 
growth of microtubules resulting in enterocytes with protruding microtubule structures 
(Schwan et al., 2009, 2014). These cell surface protrusions are postulated to contribute to the 
virulence of C. difficile by assisting the bacterium to adhere to the enterocytes and colonise 
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the intestine. While toxins A and B have been described as the main virulence factors of  
C. difficile, there have been reports of suspected CDI cases being caused by strains that only 
produced the binary toxin, and isogenic toxin A-B-Cdt+ mutants were able to cause disease 
in a hamster model (Eckert et al., 2015; Kuehne et al., 2014). 
Toxin genetics and regulation 
Pathogenic strains of C. difficile harbour a 19.6 kb pathogenicity locus (PaLoc) (Figure 1.1) 
composed of the tcdA and tcdB genes, which encode toxin A and toxin B, respectively, as 
well as tcdR, tcdC and tcdE, which are known as accessory genes (Hammond & Johnson, 
1995; Hundsberger et al., 1997).  
 
Figure 1.1 The arrangement of the genes in the C. difficile pathogenicity locus. The tcdA 
and tcdB genes are highlighted in black, while the accessory genes, tcdD, tcdE and tcdC, are 
highlighted in white. (Adapted from Hundsberger et al., 1995). 
 
The binary toxin components are also chromosomally encoded, but the cdtA and cdtB genes 
are not located in the PaLoc and are only found in some C. difficile strains (Metcalf & Weese, 
2011; Perelle et al., 1997; Popoff et al., 1988). There are various deletions in the tcdA gene 
that can result in the non-production of toxin A. These strains only encode functional toxin B 
and are referred to as toxin A-negative, toxin B-positive (A-B+) strains, whereas strains that 
can encode both toxins are toxin A-positive, toxin B-positive (A+B+) strains (Kato et al., 
1998; Lyerly et al., 1992). The most frequently isolated A-B+ strains have a deletion of  
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1.8 kb in the repeat regions of the tcdA gene, resulting in the non-production of toxin A (Alfa 
et al., 2000; Kato et al., 1999; Moncrief et al., 2000). A few other types of A-B+ strains have 
been described including one with a large deletion of 5.9 kb from the 3' end of the tcdA gene 
extending to the 5' end of the tcdC gene (Rupnik et al., 2003; Soehn et al., 1998). In addition 
to the lack of toxin A, pathogenic A-B+ strains usually encode a variant toxin B that appears 
to be a hybrid between the TcdB toxin from the reference strain, C. difficile VPI 10463, and 
the TclS lethal toxin from Clostridium sordellii (Chaves-Olarte et al., 1999; Lyerly et al., 
1992; Torres, 1991). While toxin B from the reference strain glucosylates Rho, Rac and 
Cdc42 small GTPases, the variant toxin B from A-B+ only targets Rac GTPases and shows a 
differential cytopathic effect (Huelsenbeck et al., 2007). Nevertheless, A-B+ strains have 
been responsible for several outbreaks and are still capable of severe and lethal disease (Alfa 
et al., 2000; Komatsu et al., 2003). Finally, some strains of C. difficile do not harbour the 
PaLoc, and they are referred to as A-B- or non-toxigenic strains (Fluit et al., 1991).  
The PaLoc also includes three accessory genes: tcdR, tcdE and tcdC. The tcdE gene encodes 
a putative holin-like protein that is proposed to facilitate the release of C. difficile toxins; 
however, a study has shown that the inactivation of TcdE did not significantly affect toxin 
release from C. difficile (Govind & Dupuy, 2012; Olling et al., 2012; Tan et al., 2001). The 
tcdR gene, previously referred to as tcdD, encodes an alternative RNA polymerase sigma 
factor that functions as a positive regulator in the expression of toxins A and B (Mani & 
Dupuy, 2001). The tcdC gene is proposed to encode a negative modulator of toxin expression 
and certain deletions in the gene have been found in some C. difficile strains, which show 
increased and/or prolonged toxin production (Carter et al., 2011; Curry et al., 2007; 
Matamouros et al., 2007; Warny et al., 2005). The notion that TcdC is a negative regulator, 
however, lacks strong supportive evidence and remains a subject of debate, since recent 
studies have shown that TcdC does not significantly inhibit toxin expression (Bakker et al., 
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2012; Cartman et al., 2012). The roles of TcdE, TcdC and the mutations in tcdC require 
further investigation to determine their exact contribution, if any, to the pathogenesis of  
C. difficile. An additional mechanism of toxin regulation, independent of TcdC, has been 
proposed, which involves a quorum-signalling system mediated by thiolactone, which can be 
detected in stool specimens of CDI patients (Darkoh et al., 2015). 
 
1.3 Molecular typing of C. difficile strains 
A variety of molecular typing methods have been developed to study the epidemiology of  
C. difficile. Initially, C. difficile strains were differentiated and identified based on phenotypic 
characteristics (Delmee et al., 1985; Mulligan et al., 1988). Phenotyping methods are, 
however, not reproducible and are of a low discriminatory power. They have, therefore, been 
replaced by a variety of genotypic typing methods.  
1.3.1 Restriction-based typing methods 
Pulsed-field gel electrophoresis (PFGE) and restriction endonuclease analysis (REA) involve 
the digestion of whole genomic DNA using SmaI and HindIII, respectively (Clabots et al., 
1993; Gal et al., 2005). Using REA, the digested DNA fragments are separated by agarose 
gel or polyacrylamide gel electrophoresis. The PFGE technique involves DNA fragment 
separation using agarose gel electrophoresis with the electric field orientation repeatedly 
changing in two different directions and is able to resolve the sizes of the larger fragments. In 




1.3.2 PCR amplification-based typing methods 
The amplified fragment length polymorphism (AFLP) method uses a combination of 
restriction enzyme digestion of DNA and amplification of sets of the resultant restriction 
fragments. Gel analysis of the amplified restriction fragments is then used to visualise the 
different C. difficile strain types (Klaassen et al., 2002). The arbitrarily primed polymerase 
chain reaction (AP-PCR) method involves DNA amplification using a single short primer, 
which binds non-specifically to the genome sequence. Several DNA fragments of different 
lengths are amplified creating a banding pattern when separated by agarose gel 
electrophoresis (McMillin & Muldrow, 1992; Tang et al., 1995).     
PCR ribotyping differentiates C. difficile strains based on the amplification of the 16S-23S 
rRNA intergenic spacer regions, which vary in both number and length among strains, 
thereby, creating specific banding patterns when resolved using agarose gel or capillary 
electrophoresis (Bidet et al., 1999; Stubbs et al., 1999). Each unique banding pattern is 
assigned a ribotype number. Three sets of primers have been proposed for PCR ribotyping. 
The first set of primers is widely used and a large library of PCR ribotypes has been produced 
(Stubbs et al., 1999). These primers have been revised and a second set of primers of greater 
specificity for C. difficile PCR ribotyping have been proposed (Bidet et al., 1999). More 
recently, a third set of primers of increased specificity for C. difficile have been designed for 
direct PCR ribotyping from stool specimens (Janezic et al., 2011). However, they are not as 
widely used as the first two sets of primers. With three sets of primers available, PCR 
ribotyping protocols are not standard worldwide. In addition, this method is of a low 
resolution, and requires data-portability and inter-laboratory comparability. Poor resolution 
can be improved by using the capillary gel-based PCR ribotyping method (Indra et al., 2008). 
This method involves labelling the primers with fluorescent tags and analysing the PCR 
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fragments using capillary gel-based electrophoresis. Recently, there have been attempts to 
develop internationally standardised capillary gel-based protocols that should allow a more 
efficient exchange of data between laboratories (Fawley et al., 2015). 
Multilocus variable-number tandem-repeat analysis (MLVA) is a highly discriminatory 
genotyping method that can further subtype strains within a single PCR ribotype (van den 
Berg et al., 2007; Manzoor et al., 2011; Marsh et al., 2006). MLVA involves the 
amplification of variable-number tandem-repeat loci in the genome using primers with 
fluorescent tags. The PCR products are analysed by multi-coloured fluorescence capillary 
electrophoresis. The data can be used to construct a minimum spanning tree, which depicts 
the genetic relatedness between isolates based on the summed tandem repeat differences.  
1.3.3 Sequence-based methods 
Multilocus sequence typing (MLST) is a preferred method for typing pathogens and has been 
applied to typing C. difficile (Griffiths et al., 2010; Lemée et al., 2004a). This method 
involves the PCR amplification of several reference genes followed by the nucleotide 
sequence analysis of these PCR fragments to differentiate strains. A unique combination of 
alleles is assigned its own sequence type number. The data produced by MLST can be 
applied to investigating the genetic relatedness between C. difficile isolates and the 
population structure. Online databases are available allowing laboratories to compare data 
and allowing global investigations to be conducted more easily (Griffiths et al., 2010). 
Toxinotyping distinguishes strain types based on polymorphisms in the toxin and regulatory 
genes of the PaLoc (Rupnik et al., 1998, 2001). This technique involves the PCR 
amplification of six regions in the PaLoc, followed by an RFLP analysis of the amplicons.  
The sequencing of the variable region of the slpA gene, which encodes a surface-layer protein 
A, and the entire tcdC gene have also been used as genotyping methods for C. difficile (Curry 
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et al., 2007; Joost et al., 2009; Kato et al., 2010; Spigaglia & Mastrantonio, 2002). Sequence-
based typing methods are reproducible and allow inter-laboratory data exchange.  
The most recent method, whole genome sequencing (WGS) involves determining the 
nucleotide sequence of an organism’s entire genome (Eyre et al., 2013a, b). This technique 
can distinguish C. difficile isolates belonging to the same genotype based on single nucleotide 
polymorphisms (SNPs) in the non-repetitive core region of the genome. The data generated 
by WGS also provides information regarding gene content and genetic differences among  
C. difficile strains. WGS can be used to study the population structure of C. difficile and to 
investigate the transmission of CDI. 
 
1.4 Epidemiology of various C. difficile strains and outbreaks 
There are several C. difficile strains that are currently prevalent and responsible for hospital 
outbreaks. Outbreaks occurred in Canada and the USA from the year 2000 onward, in the 
United Kingdom in 2004, and other European countries thereafter, and were found to be 
caused by the spreading of PCR ribotype 027 (Kuijper et al., 2006; Labbé et al., 2008; 
McDonald et al., 2005; Smith, 2005). Asian countries have also reported the isolation of 
ribotype 027 from CDI patients (Cheng et al., 2009; Kim et al., 2011). The ribotype 027 
clade, also known as the NAP1 group (as identified by PFGE) and the BI group (as identified 
by REA) has been investigated extensively. Clinical isolates belonging to the ribotype 027 
clade have been associated with high-level production of toxin A and toxin B over a 
prolonged period of time during infection contributing to severe disease. They have been 
associated with an 18 bp deletion and a single nucleotide deletion at position 117 in the tcdC 
gene, which introduces a frameshift mutation in the tcdC gene. This results in a truncated 
version of the TcdC protein being encoded (Warny et al., 2005). The ribotype 027 clade has 
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also been associated with the production of the additional binary toxin, increased rate of 
sporulation and resistance to several antimicrobials, such as erythromycin and 
fluoroquinolone antimicrobials (Akerlund et al., 2008; Warny et al., 2005).  
More recently, studies have reported the emergence of clinical isolates belonging to the PCR 
ribotype 017 clade in North America and Europe, and several outbreaks caused by this strain 
have been recorded (Dobreva et al., 2013; Drudy et al., 2007a; Pituch et al., 2011; Tenover et 
al., 2011). It is also prevalent in various Asian countries where the free use of antimicrobials 
without prescription may promote the spread of this strain (Hawkey et al., 2013; Lee et al., 
2014). Ribotype 017 strains do not produce a functional toxin A but are nonetheless of 
clinical interest due to their ability to still cause severe cases of CDI (Drudy et al., 2007a; 
Kim et al., 2012a).  
The emergence of the various C. difficile strains, some of which have caused severe disease 
and/or have reached epidemic proportions, has led to the need for rapid and reliable 
diagnostic tests for early detection and subsequent infection control, as unreliable tests can 
result in an under-representation of the number of CDI cases (Davies et al., 2014). 
 
1.5 CDI diagnosis 
Several clinical and laboratory diagnostic methods have been developed for CDI, each based 
on different C. difficile targets. Detection methods include targeting the C. difficile toxins A 
and/or B genes or proteins, the C. difficile glutamate dehydrogenase, or by isolation of the 
organism itself. The success rate of these detection methods can vary due to the strain type or 




1.5.1 Enzyme-immunoassay based tests 
Enzyme-immunoassay (EI-) based tests detect toxins A and B antigens in stool specimens. 
They have been the standard method for detection since the mid 1980’s and are widely 
available (Lyerly et al., 1983). However, analysis of the performances of various EI-based 
tests has shown that their diagnostic sensitivity is often poor (Eastwood et al., 2009; 
Hernández-Rocha et al., 2013; Swindells et al., 2010).  Despite the knowledge of their poor 
sensitivity, EI-based tests are rapid to perform and remain as the standard diagnostic method 
in many hospitals worldwide.  
1.5.2 Cell culture neutralisation assay 
The cell culture neutralisation assay (CCNA) detects the presence of toxin B directly in stool 
specimens. An observed cytopathic effect on the cells and neutralisation with a C. difficile 
toxin B antibody indicate a positive result. The CCNA has often been used as a reference 
method when evaluating the clinical performance of different diagnostic tests. However, 
certain studies have also reported on its poor diagnostic sensitivity (Barbut et al., 2009; 
Hernández-Rocha et al., 2013; Stamper et al., 2009; Swindells et al., 2010). In addition, this 
method is time consuming (24 – 48 hrs to perform) and requires tissue culture facilities, 
experience in tissue culture techniques and a reliable antitoxin for neutralisation, which are 
not available to many routine diagnostic laboratories.   
1.5.3 Toxigenic culture  
Toxigenic culture of C. difficile involves isolating the organism from stool specimens using 
selective media and then determining if the isolate is toxigenic. The culturing of C. difficile 
on selective media was described in the 1970’s and employed an egg-yolk fructose base, with 
either cycloserine or both D-cycloserine and cefoxitin added as the selective agents (George 
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et al., 1979). Since then, variations of the medium include reducing the antimicrobial 
concentration, including taurocholate to enhance spore germination, and replacing the egg-
yolk with blood (Levett, 1985; Wilson et al., 1982). Heat- or alcohol-shock, as well as broth 
enrichment, prior to plating on agar have been shown to enhance the recovery of C. difficile 
isolates (Arroyo et al., 2005; Marler et al., 1992; Riley et al., 1987).  
Once the bacterium has been identified, the isolate’s ability to produce biologically active 
toxins is determined. This involves growing the isolate in broth and using the CCNA or an 
enzyme-linked immunosorbent assay (ELISA) to test for active toxins in the culture 
supernatant. Alternatively, PCR screening for the toxin genes has been used to determine 
whether the isolates are potentially toxigenic (Lemée et al., 2004b). 
To combine the isolation and determination of toxin production in a single step, chromogenic 
media have been developed. One such medium contains cycloserine and cefoxitin as selective 
agents, as well as a chromogenic substrate (5-bromo-4-chloro-3-indoxyl-β-D-
galactopyranoside) (Darkoh et al., 2011a). This substrate has similar stereochemical 
characteristics to UDP-glucose, which is naturally used by toxins A and B as a co-substrate to 
inactivate proteins. Hydrolysis of the substrate during the growth of toxin-producing strains 
produces blue colonies, while the colonies of non-toxigenic strains remain white.  
1.5.4 Nucleic acid amplification tests 
In recent years diagnostic tests have developed considerably and there has been a shift to 
using nucleic acid amplification tests (NAATs). These show a high level of diagnostic 
sensitivity when compared to the CCNA and toxigenic culture methods, but tend to be 
expensive and are not able to identify whether C. difficile strains are actively producing toxin 
during an infection (Swindells et al., 2010). With the gradual replacement of EI-based tests 
18 
 
with NAATs in various laboratories, the reported detection of C. difficile has increased 
(Grein et al., 2014; Longtin et al., 2013). This is not necessarily a reflection of an increase in 
the incidence of C. difficile, but may be a representation of the formerly undetected cases of 
CDI. 
1.5.5 Diagnostic test algorithms 
While some of the abovementioned diagnostic methods are regarded as more reliable than the 
others, accurate diagnosis still remains a problem. There has been debate whether detection 
of the various species-specific genes using NAATs is an indication of a true disease state, 
since CDI is mediated by the encoded toxins and the presence of toxin genes alone does not 
necessarily imply sufficient levels of the organism to cause disease (Baker et al., 2013). 
Several laboratories have adopted two-step or three-step algorithms for the accurate diagnosis 
of CDI (Gilligan, 2008; Goldenberg et al., 2010; Novak-Weekley et al., 2010; Sharp et al., 
2010). The first test in the algorithm is often the detection of C. difficile glutamate 
dehydrogenase (GDH) to confirm the presence of the organism in stool specimens. However, 
screening for GDH does not differentiate between non-toxigenic (A-B-) and toxigenic (A-B+ 
or A+B+) strains. Screening for GDH is, therefore, followed by an assay screening for the 
toxin genes and/or biologically active toxins. Combining diagnostic tests is more time 
consuming and labour intensive, but it produces more accurate diagnostic results and has the 
potential to reduce the overall number of tests required. Repeating a diagnostic test is 
discouraged in many countries, therefore, it is imperative that diagnostic methods are as 
accurate as possible.  
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1.6 Treatment of CDI 
1.6.1 Antimicrobial treatment - metronidazole and vancomycin 
Controlled use of broad-spectrum antimicrobials and the use of effective treatment methods 
are necessary to avoid and control outbreaks of CDI. Metronidazole and vancomycin have 
been, and still are, the most commonly administered antimicrobials for the treatment of CDI 
(Debast et al., 2014). Metronidazole is used to clinically treat a wide range of anaerobic 
infections and is the preferred treatment option for patients with mild to moderate cases of 
CDI (Zar et al., 2007). Metronidazole is a 5-nitroimidazole agent, which is activated within 
anaerobic bacterial cells during bacterial anaerobic metabolism to form a reactive nitrogen 
radical. The active metronidazole causes DNA strand breakage resulting in bacterial cell 
death (Dachs et al., 1995; Edwards & Mathison, 1970). Vancomycin is produced by 
Streptomyces orientalis and it inhibits the biosynthesis of peptidoglycan (Hammes & 
Neuhaus, 1974). Vancomycin has been shown to be superior to metronidazole and more 
effective in severe cases of CDI (Zar et al., 2007). However, it is significantly more 
expensive and its use has led to the emergence of vancomycin-resistant Enterococcus strains 
(Al-Nassir et al., 2008a; Nerandzic et al., 2012). It is, therefore, reserved for treatment failure 
or severe cases (Baines et al., 2009; Al-Nassir et al., 2008b).  
1.6.2 Other antimicrobials 
Fidaxomicin is a recently approved antimicrobial for the treatment of CDI. Fidaxomicin, also 
known as OPT-80, belongs to a new class of macrocyclic antimicrobials that is secreted by 
Dactylosporangium aurantiacum (Theriault et al., 1987). It is a narrow-spectrum 
antimicrobial, which displays activity against C. difficile, by inhibiting RNA polymerase 
during transcription, and causes minimal disruption of the enteric microbiota (Artsimovitch et 
al., 2012; Finegold et al., 2004; Tannock et al., 2010). Compared to vancomycin, 
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fidaxomicin has been found to be as effective in the treatment of CDI and superior in 
reducing the recurrence of CDI (Crook et al., 2012; Louie et al., 2011). In a human gut 
model, fidaxomicin was able to reduce the total viable count of C. difficile within a shorter 
period of time than vancomycin, while metronidazole failed to do so (Chilton et al., 2014). In 
addition, fidaxomicin was able to reduce C. difficile spores in the gut model and the 
antimicrobial was able to persist over a longer period of time than both vancomycin and 
metronidazole. However, the high cost of fidaxomicin prevents it from being used widely.  
Tigecycline is a broad-spectrum tetracycline derivative that has shown activity against  
C. difficile in vitro and has been successfully used to treat patients with severe cases of CDI 
(Britt et al., 2014; Herpers et al., 2009). Rifaximin, belonging to the rifamycin class of 
antimicrobials, has also been shown as a possible treatment option for severe cases of CDI 
(Kokkotou et al., 2008; Mattila et al., 2013). While these antimicrobials may be effective 
treatment options, there are insufficient clinical data at present to support their routine use. 
1.6.3 Antimicrobial resistance 
Reported reduced susceptibility or resistance of C. difficile to antimicrobials in association 
with CDI has raised interest in investigating the mechanisms responsible for these 
observations. Reduced susceptibility and resistance to metronidazole have been reported in a 
few C. difficile strains (Baines et al., 2008; Brazier et al., 2001; Peláez et al., 2008). 
Metronidazole concentrations that can be achieved in the intestine are as low as 
approximately 9.5 µg/g faeces, which, may not be able to inhibit strains with reduced 
susceptibility and could lead to treatment failure (Bolton & Culshaw, 1986). This has raised 
concern regarding the effective treatment of CDI and warrants the need to monitor 
antimicrobial susceptibility in vitro. The exact mechanism for metronidazole resistance in  
C. difficile is poorly understood. In Bacteroides fragilis, an anaerobic bacterium that causes 
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gastrointestinal infections, various nitroimidazole genes (nimA-J) encode nitroreductases, 
which are thought to inactivate metronidazole (Gal & Brazier, 2004; Haggoud et al., 1994; 
Husain et al., 2013). PCR screening has shown that B. fragilis nim homologues are present in 
other species including one strain of Clostridium bifermentans (Lubbe et al., 1999). While 
nim homologues have not yet been detected in C. difficile, a recent proteomic study reported 
the increased expression of several proteins, including putative 5-nitroimidazole reductases in 
a stable metronidazole resistant C. difficile strain even in the absence of metronidazole 
(Chong et al., 2014). 
There are very few reports of reduced susceptibility or resistance to vancomycin in  
C. difficile (Chia et al., 2013). This may be explained by the high vancomycin concentrations 
(1000-5000 µg/ml) that can be maintained in the intestine (Edlund et al., 1997). While in 
vitro induction methods have allowed the identification of several mutations that lead to a 
reduced susceptibility to vancomycin in C. difficile, the clinical significance of these 
mutations is unclear (Leeds et al., 2014). Recurrence of CDI after the use of metronidazole or 
vancomycin has been reported and has prompted the development of alternative therapeutic 
methods (Pépin et al., 2007). 
Clindamycin and erythromycin are macrolide–lincosamide–streptogramin B (MLSB) agents, 
which inhibit protein synthesis (Tenson et al., 2003). The most widely described resistance 
mechanism is the dimethylation of the 23S rRNA gene by a 23S rRNA methylase encoded by 
the erythromycin ribosomal methylase (ermB) gene. High-level resistance to these 
antimicrobials in C. difficile is associated with the presence of the ermB gene, which is 
usually located on a mobilisable genetic element such as the transposon Tn5398  (Johnson et 
al., 1999).  
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Moxifloxacin has been shown to promote bacterial growth of, and toxin production by, 
fluoroquinolone-resistant epidemic C. difficile strains (Adams et al., 2007). This class of 
antimicrobials is selective for highly resistant C. difficile strains. Ciprofloxacin and 
moxifloxacin are second and third generation fluoroquinolones, respectively, which interact 
with the DNA gyrase subunits A and B that are involved in DNA replication (Hooper, 1999). 
The interaction results in DNA breakage. C. difficile fluoroquinolone resistance has been 
associated with gyrA and gyrB mutations, which result in amino acid substitutions in the 
encoded proteins (Dridi et al., 2002). 
Tetracycline is another broad-spectrum antimicrobial that inhibits protein synthesis (Chopra 
& Roberts, 2001). Resistance to tetracycline is mediated by the tetM gene, which is usually 
located on Tn916-like transposons such as Tn5397 (Mullany et al., 1990). Tetracycline 
resistance is commonly associated with erythromycin resistance, and certain studies have 
observed a physical link between the ermB and tetM genes (Spigaglia et al., 2007). Having 
these genetic resistance determinants located on mobilisable genetic elements allows intra- 
and interspecies exchange, aiding in the spread of antimicrobial resistance (Mullany et al., 
1990; Wasels et al., 2014).  
Alternative antimicrobial resistance mechanisms in bacteria involve efflux systems, some of 
which are specific to MLSB and fluoroquinolone antimicrobials (Ambrose et al., 2005; 
Martinez-Garriga et al., 2007). Bacterial genes encode efflux proteins that pump the 
antimicrobial out of the cell keeping intracellular concentrations below lethal levels (Lin et 
al., 2015; McMurry et al., 1980; Saiful et al., 2008). However, very few studies have 
investigated these systems in C. difficile, and so their contribution to antimicrobial resistance 
in CDI is not known (Dridi et al., 2004; Lebel et al., 2004).  
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1.6.4 Alternative treatment methods 
Problems related to antimicrobial resistance and the recurrence of CDI after antimicrobial 
treatment have led to the development of alternative treatment methods. Faecal 
transplantation, which involves the transfer of stool from a healthy individual into the colon 
of an infected individual, has been shown to be an effective treatment option for patients with 
recurrent CDI (Kelly et al., 2012; van Nood et al., 2013). If successful, this treatment option 
restores a healthy balance to the enteric microbiota, thus supressing the prevalence of  
C. difficile. Alternatively, the colon of a patient with recurrent CDI can be infused with a 
combination of pure cultured bacterial species that make up the normal and protective 
microbiota of a healthy individual (Tvede & Rask-Madsen, 1989). Other non-antimicrobial 
treatment options have been suggested for the treatment of CDI including the use of 
probiotics to provide a protective barrier of low-virulence microorganisms against C. difficile, 
the use of toxin-binding polymers, or the use of immunotherapy whereby neutralising 
antibodies target C. difficile toxins (van Dissel et al., 2005; Lawrence et al., 2005; Mogg et 




C. difficile forms endospores, which survive and may remain dormant in the host intestine 
and are subsequently shed by CDI patients. C. difficile spores are resistant to many 
environmental and antimicrobial factors (Dawson et al., 2011; Fawley et al., 2007; 
Goldenberg et al., 2012). This enables them to persist in hospital environments over a long 
period of time creating a reservoir for transmission (Sjöberg et al., 2014). Transmission in 
hospital environments can also be aided by the contamination of healthcare workers, and this 
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has increased the importance of washing hands and disinfecting hospital surfaces regularly 
(Bobulsky et al., 2008; Guerrero et al., 2012; Landelle et al., 2014). However, disinfectants 
have also been reported to increase sporulation and antimicrobial treatment can reportedly 
induce super-shedding of spores by CDI patients (Lawley et al., 2009; Wilcox & Fawley, 
2000).  
The rate of sporulation can vary between C. difficile strains. Published studies have reported 
that isolates of epidemic clades, such as ribotypes 001 and 027, have an increased sporulation 
frequency in vitro, which may enable them to persist and spread more easily (Akerlund et al., 
2008; Merrigan et al., 2010; Vohra & Poxton, 2011; Wilcox & Fawley, 2000). These studies, 
however, analysed only a few isolates and, therefore, do not provide a true representation of 
sporulation characteristics in the various strains. More recent studies, using a larger sample 
size, have reported that the sporulation frequency of ribotype 027 strains was not higher than 
non-027 strains. In addition, there was variation in sporulation among isolates belonging to 
ribotype 027, suggesting that the frequency was not associated with the strain type (Burns et 
al., 2010, 2011). 
 
1.8 Colonisation of the host intestine 
In order to cause disease, C. difficile must first colonise the host intestine. Colonisation is 
initiated by the germination of ingested spores. This is followed by the proliferation of 
vegetative cells, which then adhere to colonic mucus, and likely, to the host enteric cells and 
colonise the intestine. Very little is known about the colonisation mechanism of C. difficile. 
However, some strains may bind more robustly to human intestinal epithelial cells than other 
strains, providing an advantage during colonisation (Merrigan et al., 2013). Several other 
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factors have also been proposed to play a role in adherence and colonisation and it is likely 
that the process is a multi-factorial one.  
Certain cell surface proteins of C. difficile have been identified and may facilitate adherence 
to other bacterial cells and/or to the host. The C. difficile flagellar proteins, FliC and FliD, 
have been proposed to play a role in the adherence to mucus, which is the first barrier 
encountered before reaching the intestinal tissue (Tasteyre et al., 2001). Recently,  
C. difficile R20291 fliC and fliD mutant strains have been shown to display decreased 
adherence to Caco-2 cells when compared to the wild type strain (Baban et al., 2013). 
However, similar C. difficile 630 mutant strains were able to adhere better to Caco-2 cells 
than the wild type strain, suggesting that the role of flagella in adherence may vary across 
strains (Dingle et al., 2011b). Other flagellar modifications may also play a role in adherence 
and cell aggregation (Faulds-Pain et al., 2014). 
Adhesins are an attractive target for vaccine development and, therefore, the characterisation 
of the various adhesins and their roles in bacterial attachment would be of value. A 
fibronectin-binding protein, Fbp68, and a heat shock protein, GroEL, of C. difficile reportedly 
play a role in adherence (Hennequin et al., 2003). The C. difficile lipoprotein CD0873 is a 
surface protein shown to adhere to Caco-2 cells, while a non-CD0873-expressing mutant was 
unable to do so (Kovacs-Simon et al., 2014). Another factor suggested to contribute to 
adherence and aggregation is cyclic diguanylate, through regulation of the expression of type 
IV pili (Bordeleau et al., 2015; Purcell et al., 2012). 
A large family of cell wall proteins (CWPs) of C. difficile have been identified and may play 
a role in adherence. One major CWP is surface layer protein SlpA, which is encoded by the 
slpA gene and post-translationally processed to form the high- and low-molecular weight 
subunits. These assemble together on the surface of the cell to form a paracrystalline lattice 
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(Takeoka et al., 1991). Purified SlpA has been shown to adhere to Caco-2 cells, and this 
binding was inhibited by anti-SlpA antibodies (Merrigan et al., 2013).  Other CWPs include 
Cwp66 and Cwp84. The Cwp66 is an adhesin that has been shown to facilitate bacterial 
adherence to Vero cells as the addition of two antibodies raised against the protein reduced 
adherence (Waligora et al., 2001). The Cwp84 is a protease that processes immature SLPs 
into the high molecular weight and low molecular weight SLPs and may play a role in 
modulating biofilm formation (Kirby et al., 2009; Pantaléon et al., 2015). Cwp84 has also 
been shown to cleave proteins of the host-cell extracellular matrix thereby reducing the 
integrity of the host tissue (Janoir et al., 2007). 
CwpV is a recently identified adhesin of C. difficile (Emerson et al., 2009; Reynolds et al., 
2011). The protein consists of an N-terminal domain, which is conserved between different 
strains and is proposed to anchor the protein to the cell wall. The C-terminal domain 
facilitates adherence between C. difficile cells, thereby promoting aggregation, which may 
contribute towards biofilm formation. The C-terminal domain consists of repeated amino 
acids, with the number of repeats varying between strains, and inducing different levels of 
auto-aggregation of C. difficile (Reynolds et al., 2011). C. difficile has been shown to 
aggregate to form biofilms, which aids in survival and colonisation (Dapa et al., 2013; 
Dawson et al., 2012). However, CwpV has not yet been linked specifically to biofilm 
formation. 
CwpV is encoded by the cwpV gene, and its expression is phase-variable. Previously it has 
been shown that only 10% of the cells within a population express CwpV in vitro (Emerson 
et al., 2009; Reynolds et al., 2011). Upstream of the start codon of cwpV is a 195 bp 
nucleotide sequence flanked by inverted repeats (Figure 1.2). DNA inversion of this region is 
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mediated by a recombinase, probably RecV, and allows expression of cwpV in one 
orientation (ON), while in the other orientation the gene is not transcribed (OFF).  
 
 
Figure 1.2 The inversion region upstream of the cwpV gene. A pair of 21 bp inverted 
repeats (IRs) separated by 195 bp and located between the promotor (P) and the cwpV gene. 
(Adapted from Emerson et al., 2009) 
 
A study investigating CwpV expression in various C. difficile strains identified a strain that 
did not express the protein (Emerson et al., 2009). While this strain harboured the cwpV gene, 
PCR analysis targeting the inversion region revealed that only the OFF orientation was 
present, whereas, both the ON and OFF orientations were detected in C. difficile strains that 
expressed CwpV. Interestingly, the non-expressing strain had a two-nucleotide deletion in 
one of the inverted repeat sequences, which could potentially prevent processing by the 
recombinase responsible for the inversion, thus ‘locking’ the region in the OFF orientation. 
The function of CwpV in auto-aggregation and colonisation still has to be verified. A recent 
study has shown that this protein, specifically the C-terminal domain, has anti-phage activity 
(Sekulovic et al., 2015). In addition, cells with the ON orientation were expressing cwpV and, 




1.9 Project aim 
Extensive research has been conducted in Canada, USA, various European countries, 
Australia and various Asian countries to gain insight into the pathogenicity of C. difficile and 
establish the regional epidemiology of CDI with a view to containing the severity and extent 
of the disease. Research has shown that strain prevalence differs geographically and over 
time. Therefore, it is necessary for each country to conduct local surveillance to order to 
understand the pathogenesis and epidemiology of C. difficile strains in their respective 
settings.  
Very few studies regarding C. difficile in South Africa have been published. One study was 
conducted in the Vhembe district, in the Limpopo Province (Samie et al., 2008), where the 
prevalence of toxigenic C. difficile strains in stool specimens provided by hospitalised 
patients and primary school children was estimated by PCR screening for the tpi, tcdA, tcdB, 
tcdC and binary toxin genes. Toxigenic C. difficile was detected in approximately 11% of 
diarrhoea specimens. Another study monitored C. difficile among diarrhoea patients attending 
the Steve Biko Academic Hospital in Pretoria, in the Gauteng Province, using an EI-based 
assay targeting toxin A only in stool specimens (Lekalakala et al., 2010). However, the 
overall incidence of toxigenic C. difficile was not reported and the assay would not have 
detected pathogenic strains that did not produce toxin A. Another study, also using an EI-
based assay targeting toxin A only, conducted at Groote Schuur Hospital in Cape Town, in 
the Western Province, reported a 9.2% incidence of CDI among symptomatic patients 
(Rajabally et al., 2013).  In addition, this study identified two CDI cases possibly caused by 
ribotype 027 isolates, based on the PCR detection of the 18 bp deleted version of the tcdC 
gene in the patient specimen. However, this 18 bp deletion is also present in non-027 strains 
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and is, therefore, not a valid marker for the identification of an isolate belonging to the 
ribotype 027 clade (Curry et al., 2007).  
With the spread and outbreaks of CDI worldwide and the increase in prevalence of 
antimicrobial resistance, it is essential to begin the monitoring and characterisation of South 
African C. difficile strains in order to administer active therapy and implement effective 
infection control protocols. Prior to the initiation of this project, Groote Schuur Hospital 
made use of the EI-based ImmunoCard Toxins A & B (Meridian Bioscience, Inc) diagnostic 
test. However, its clinical performance within the local setting had not been determined. 
Therefore, the aims of this project were to evaluate current local methods of diagnosing CDI 
and to conduct a molecular characterisation of C. difficile strains isolated from symptomatic 
patients at Groote Schuur Hospital. The study planned to isolate C. difficile from 
symptomatic patients and to type these bacteria by PCR ribotyping, sequencing of the tcdC 
gene and MLVA. The susceptibility of the C. difficile isolates to various antimicrobials, both 
those used in treatment and those known to be risk factors for the development of CDI, would 
be determined, as well as the underlying genetic resistance mechanisms. The abilities of the 
isolates to produce biologically active toxins and to sporulate would also be investigated. 
Finally, auto-aggregation, which may be important during biofilm formation and host 
colonisation, would be investigated in all the isolates. 
This thesis, therefore, reports the results of a pilot study carried out to investigate C. difficile 
strains responsible for clinical infections at a major hospital in South Africa. The 
characterisation and analysis of pathogenic strains infecting patients attending Groote Schuur 
Hospital will provide a better understanding of the bacterium and how it causes disease.  
Information collected during this project can be further used to help guide improvements in 
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the prevention and treatment of CDI at Groote Schuur Hospital and other medical centres in 
South Africa.  
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2.0 Abstract 
Clostridium difficile is a toxin-producing, anaerobic pathogen of increasing clinical interest 
worldwide. It is responsible for life-threatening gastrointestinal diseases, known as C. difficile 
infection (CDI), and is the leading cause of nosocomial, antimicrobial-associated diarrhoea. 
The prevalence of CDI in South Africa is not known at present. In this study, stool specimens 
were collected from 162 symptomatic patients at Groote Schuur Hospital. C. difficile was 
isolated from 34/162 specimens (20% prevalence) by toxigenic culture using selective media. 
A multiplex PCR identified the C. difficile species-specific tpi gene fragment and three 
toxigenic-types: A+B+ (47% of strains), A-B+ (47%) and A-B- (6%). The binary toxin genes 
were not present in any of the clinical isolates. Rapid and reliable diagnostic methods to 
identify CDI are necessary to help improve infection control. In this study, four clinical 
diagnostic tests were analysed and compared to the reference method of toxigenic culture 
described above. The enzyme immunoassay-based tests, Meridian ImmunoCard and 
bioMérieux MiniVidas, had low diagnostic sensitivities of 37.5% and 50%, respectively. The 
nucleic acid amplification tests, Hain Lifescience CDiff and Cepheid GeneXpert, had 
sensitivities of 87.5% and 90.6%, respectively. The GeneXpert performed the best and is 
recommended for the future clinical diagnosis of CDI at Groote Schuur Hospital.  
  
 33  
 
2.1 Introduction  
Clostridium difficile infection (CDI) is a significant problem affecting individuals within 
healthcare facilities, where it is responsible for approximately 15 to 25% of antimicrobial-
associated diarrhoea cases (Bartlett & Gerding, 2008; Bauer et al., 2011). Nosocomial 
outbreaks have been reported and studied in the last decade, especially in Canada, the USA 
and Europe (Labbé et al., 2008; Warny et al., 2005). In recent years, published studies have 
also begun to emerge from Asia, Australia and Latin America (Cheng et al., 2009; King et 
al., 2015; Quesada-Gómez et al., 2010; Riley et al., 2009). However, the occurrence and 
epidemiology of C. difficile in South Africa has yet to be determined. 
Rapid and reliable detection methods are important for early detection and implementation of 
therapy and infection control. As discussed in Chapter 1, several options are available for the 
diagnosis of CDI. However, there have to date been no studies evaluating the diagnostic 
performance of any of the available tests in the local setting. The data obtained from such an 
evaluation would help identify the most appropriate diagnostic approach for local 
laboratories.   
Enzyme-immunoassay (EI)-based tests are rapid and easy to use, however, they have been 
shown to have a poor diagnostic sensitivity (Eastwood et al., 2009; Hernández-Rocha et al., 
2013; Swindells et al., 2010). Two examples of EI-based tests that are in widespread use are 
the Meridian ImmunoCard Toxins A & B assay (Meridian Bioscience, Inc. Cincinnati, OH) 
and the bioMérieux MiniVidas assay (BioMerieux, Marcy l’Etoile, France), both of which 
use antitoxin antibodies. The ImmunoCard involves a chromogenic substrate which produces 
a blue product upon hydrolysis, which is analysed visually. The MiniVidas is an automated 
enzyme-linked fluorescent immunoassay assessed using the MiniVidas platform. 
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Several newer nucleic acid amplification tests (NAATs) have also been developed. They 
screen for the presence of C. difficile specific genes, and have been shown to have improved 
diagnostic sensitivity over EI-based tests (Eastwood et al., 2009; Hernández-Rocha et al., 
2013; Swindells et al., 2010).  The Cepheid Xpert C. difficile assay (Cepheid, Sunnyvale, 
CA, United States) is a fully automated procedure performed in a GeneXpert instrument. The 
system involves DNA extraction by sonication, real-time PCR and detection of the toxin B 
gene (tcdB), the binary toxin cdtB gene and a version of the tcdC gene with a single 
nucleotide deletion at position 117. The positive detection of all these targets presumptively 
identifies the presence of C. difficile ribotype 027 in the specimen from the patient. An 
alternative NAAT is the Hain GenoType CDiff assay (Hain Lifescience SA (Pty) Ltd) which 
targets the tpi, tcdA, tcdB, cdtA, cdtB, tcdC and gyrA genes as well as a further C. difficile-
specific target not disclosed by the manufacturer. DNA is extracted either manually or using 
an automated instrument, followed by conventional multiplex PCR using a primer mix 
supplied by the manufacturer. Detection of the various targets is performed by reverse 
hybridisation of the PCR products to a strip containing membrane-bound probes. This test 
can differentiate between non-pathogenic C. difficile isolates, various toxigenic strains and 
isolates belonging to the ribotype 027 clade. 
A suitable reference method is important for the comparison of different diagnostic methods. 
Cell culture neutralisation assays (CCNA) have been used in the past for this purpose 
(Hernández-Rocha et al., 2013; Swindells et al., 2010). However they are difficult to perform 
and may lack sensitivity (Barbut et al., 2009; Stamper et al., 2009). An alternative reference 
method is toxigenic culture, which has the additional advantage of allowing for further 
characterisation and molecular tracking of isolates and is useful in epidemiological analyses. 
A variety of selective media for C. difficile are commercially available. One popular medium 
is the chromogenic medium, ChromID, which is manufactured by bioMérieux and yields 
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grey/black toxigenic C. difficile colonies. This medium has been found to be equal, and even 
superior, to other media in the isolation of spores and vegetative cells, respectively 
(Boseiwaqa et al., 2013; Perry et al., 2010). 
 Confirmation of potential C. difficile isolates from various selective media can be carried out  
by amplification of a 230 bp fragment of the tpi gene, which was found to be more 
discriminatory than using 16S rRNA gene amplification to differentiate C. difficile from other 
Clostridium species (Dhalluin et al., 2003). To simultaneously confirm the identity of a  
C. difficile isolate and determine its toxigenic type, a multiplex PCR targeting the C. difficile 
species-specific fragment of the tpi gene, and internal fragments of the toxin A and B genes, 
has also been designed (Lemée et al., 2004b). The primers designed to target the tcdA gene 
span the region commonly deleted in toxigenic A-B+ strains resulting in fragments of 110 bp 
and 369 bp for toxigenic A-B+ and A+B+ strains, respectively (Lemée et al., 2004b). 
Prior to the initiation of this project, the Groote Schuur Hospital (a large clinical tertiary 
institution in Cape Town, South Africa) made use of the EI-based ImmunoCard Toxins A & 
B (Meridian Bioscience, Inc). In a previous study, an alternative EI-based assay targeting 
toxin A only, reported a 9.2% incidence of C. difficile among symptomatic patients attending 
Groote Schuur Hospital (Rajabally et al., 2013). The aim of the work reported in this chapter 
was to investigate the prevalence of toxigenic C. difficile in symptomatic patients attending 
Groote Schuur Hospital using selective culture methods and gene-specific PCR, and to 
evaluate the performance of two EI-based assays as well as two nucleic acid amplification 
tests (NAATs) in the clinical diagnostic setting. 
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2.2 Materials and Methods 
2.2.1 Bacterial strains 
A non-toxigenic C. difficile strain (ATCC 700057) was obtained from the American Type 
Culture Collection (ATCC; Manassas, VA). C. difficile strain 709 is a toxigenic A+B+CDT+ 
strain, kindly provided by Professor Andrej Weintraub, originally obtained from a patient 
attending the Karolinska University Hospital, Stockholm, Sweden. 
2.2.2 Clinical specimens 
Stool specimens were collected from 162 symptomatic in- and out-patients attending Groote 
Schuur Hospital between March 2012 and March 2013. Symptoms were defined as diarrhoea, 
with two or more runny stools per day for at least two days (Barbut et al., 2007). 
2.2.3 Media and growth conditions 
Three types of selective media were used in this project (Table 2.1). The ChromID  
C. difficile medium (CHR) was purchased as pre-poured plates from the manufacturer 
(bioMérieux). The Oxoid (OXO) medium was prepared as needed using the Clostridium 
difficile agar base manufactured by Oxoid. The Darkoh et al. (2011a) chromogenic selective 
medium (DCS) was also prepared as needed using published basic components (Darkoh et 
al., 2011a). Both the OXO and DCS media were supplemented with defibrinated horse blood 
and the selective supplements D-cycloserine (250 µg/ml final concentration) and cefoxitin (8 
µg/ml final concentration; Oxoid). 
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Table 2.1 Selective media 
Medium Selection method Positive identity Reference/Source 
CHR 
Selective agents are not disclosed by the 
manufacturer Black colonies* bioMérieux 
 DCS 
Selection by D-cycloserine (250 µg/ml) 
and cefoxitin (8 µg/ml), and 
differentiation between toxin-positive 
and toxin-negative strains by 
chromogenic substrate (X-gal) 
Blue colonies 
Darkoh et al., 
2011 
OXO 
Selection by D-cycloserine (250 µg/ml) 




* Some strains of C. difficile did not yield black colonies on the CHR medium (Boseiwaqa et al., 2013; Perry et al., 2010). 
 
Stool specimens from symptomatic patients were streaked directly onto each of the selective 
media and the agar plates were incubated at 37ºC for 48 hours in an anaerobic chamber 
(Model 1024, Forma Scientific Inc., Marietta, Ohio) with atmospheric conditions of N2, CO2 
and H2 (85:10:5 by volume). Non-toxigenic C. difficile ATCC 700057 was used for media 
quality control every time a new batch of media was used. The bioMérieux medium was 
incubated for 48 hours instead of the manufacturer’s recommendation of 24 hours to 
maximise the isolation of C. difficile (Eckert et al., 2013). C. difficile was isolated based on 
colony morphology and/or colour change and sub-cultured on pre-reduced Brain Heart 
Infusion (BHI) (Difco) media supplemented with cysteine (0.5 mg/ml final concentration) 
(Oxoid). 
2.2.4 C. difficile identification and toxigenic typing by PCR analysis 
DNA template was prepared by suspending single colonies picked from BHI agar in 300 µl 
suspension buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8) containing proteinase K  
(1% v/v). The suspended cells were incubated for 15 min at 37ºC, followed by 30 min at  
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80ºC. Cellular debris was removed by centrifugation (6000 x g for 2 min) and 4 µl 
supernatant was used as template in the various PCR experiments. Genomic DNA extracted 
from C. difficile strain 709 was used as a positive control in all reactions. 
All isolates were screened for the C. difficile species-specific tpi fragment, the toxin A (tcdA) 
(full-length or truncated) and toxin B (tcdB) genes in a single multiplex PCR (Lemee et al., 
2004). In a separate multiplex PCR, isolates were screened for the binary toxin genes (cdtA 
and cdtB) (Stubbs et al., 2000), using primers listed in Table 2.2. 
 
Table 2.2 Primers used for C. difficile identification and toxigenic typing 
Target gene Primer sequence (5'  3') Size* (bp) Reference 
tpi 
F: AAAGAAGCTACTAAGGGTACAAA 
R: CATAATATTGGGTCTATTCCTAC 230 





369 or 110 


















Stubbs et al., 
2000 
* The 110 bp fragment refers to a truncated tcdA gene fragment. 
 
All PCRs were performed in a 50 µl reaction volume containing Kapa Taq ReadyMix (Kapa 
Biosystems), 1 µM of each tcd primer and 0.5 µM of each tpi primer. Alternatively, 0.5 µM 
of each cdt primer was used in a separate reaction. All reactions in this study were performed 
on the GeneAmp PCR System 9700 (Applied Biosystems) unless stated otherwise. The 
reactions were subjected to thermal cycling conditions previously described (Lemee et al., 
2004b; Stubbs et al., 2000) PCR products were resolved by electrophoresis on a 2% agarose 
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gel stained with ethidium bromide, and analysed with a ChemiDoc XRS+ with Image Lab 
Software (Bio-Rad). 
2.2.5 Clinical diagnostic assays 
Four clinical diagnostic tests were used to determine the presence of C. difficile in stool 
specimens (Table 2.3). The ImmunoCard, MiniVidas and GeneXpert were conducted in 
parallel to culture on selective media in the Microbiology Laboratory of the National Health 
and Laboratory Services (NHLS) at Groote Schuur Hospital. The GenoType CDiff assay 
(Hain Lifescience) was conducted by Dr Brian Kullin at the Department of Molecular and 
Cell Biology at the University of Cape Town. Each test was performed according to the 
manufacturers’ instructions. 
 
Table 2.3 Diagnostic tests 
Diagnostic test Target Comment 
ImmunoCard Toxins A & B 
(Meridian Bioscience, Inc) 
C. difficile toxins A and B  
MiniVidas C. difficile 
Toxin A & B (bioMérieux) 
C. difficile toxins A and B  
GeneXpert C. difficile 
(Cepheid) 
The tcdB and cdtA genes, 
and the Δ117 variant of 
the tcdC gene 
A positive result for all the targets  
is a presumptive indication of an 
isolate belonging to the ribotype 
027 clade 
GenoType CDiff (Hain 
Lifescience) 
The tpi, tcdA, tcdB, cdtA, 
cdtB, tcdC and gyrA 
genes as well as a further 
C. difficile-specific target 
not disclosed by the 
manufacturer 
Differentiates between non-
pathogenic, virulent and ribotype 
027 isolates 
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Sensitivity, specificity and predictive values for each of the tests were calculated relative to 
the positive identification of C. difficile by culture on selective media followed by the tpi, 
tcdA and tcdB multiplex PCR (Table 2.4) (Lalkhen & McCluskey, 2008).   
 
Table 2.4 Formulae used to calculate Sensitivity, Specificity, Positive and Negative 








𝑇𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
 
Positive predictive value 
𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒
 
Negative predictive value 
𝑇𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠




2.3 Results and Discussion 
2.3.1 Prevalence of C. difficile in stool specimens at Groote Schuur Hospital as 
determined by bacterial culture 
The prevalence of C. difficile in patients attending Groote Schuur Hospital was investigated. 
A total of 164 stool specimens from 162 symptomatic patients (two patients provided two 
specimens each) were tested using a combination of three selective media. The bacterium was 
isolated and positively identified from 34 stool specimens (listed in Table 2.5), of which 32 
were positive for at least one of the toxin genes, representing 20% prevalence of toxigenic   
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C. difficile among the 162 patients. This is approximately double the prevalence observed in 
the previous study amongst diarrhoea patients at the same site between 2010 and 2011, which 
determined a 9.2% incidence of toxigenic C. difficile (Rajabally et al., 2013). However, the 
previous study used an EI-based assay targeting toxin A only and, therefore, would not have 
detected A-B+ strains. There have only been two other published C. difficile detection studies 
performed in South Africa and these were both conducted using different study designs and 
in geographically distinct populations making inter-study comparisons difficult. A review 
regarding the detection of C. difficile using an EI-based assay targeting toxin A only in stool 
specimens from diarrhoea patients attending Steve Biko Academic Hospital in Pretoria, in the 
Gauteng Province, reported that 46 of 266 (17.2%) stool specimens tested positive during the 
study year (Lekalakala et al., 2010). However, the 46 positive specimens were obtained as 
repeat specimens from only 26 patients and it is, therefore, not possible to calculate the 
overall prevalence of C. difficile for their study. The only published PCR-based study in 
South Africa to date was conducted in the Vhembe district, in the Limpopo Province, and 
reported a prevalence of 11.4% for toxigenic C. difficile in stool specimens from individuals 
with diarrhoea, as detected by direct PCR screening for the tpi, toxins A and B, and binary 
toxin genes (Samie et al., 2008). The study population included hospitalised patients as well 
as patient members from the surrounding community with diarrhoea. Further studies are 
needed to determine the burden of C. difficile infection in South Africa. 
Different selective media have been employed to isolate C. difficile from stool specimens. In 
this project, the stool specimens were cultured on each of three types of selective media to 
maximise the isolation of C. difficile, as represented in Figure 2.1. The bacterium was 
identified based on colony morphology and/or colour change according to the various 
selective media. The CHR medium was the most effective in selecting for C. difficile when 
isolating cells directly from non-heat- or -alcohol-shocked stool, and most isolates were 
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obtained from this medium. Fewer isolates were obtained from the DCS and OXO media, as 
there often was an overgrowth of non C. difficile isolates, suggesting that these media are not 
sufficiently selective to analyse stool specimens without prior heat- or alcohol-shock 
procedures.    
 
 
Figure 2.1 Representative agar plates of the three types of selective media used in this 
study: a) Darkoh chromogenic selective (DCS) medium*, b) ChromID (CHR) medium and 
c) Oxoid (OXO) medium. 
* Toxigenic C. difficile isolates grow as blue colonies on the DCS medium, which is not represented in the figure above. 
 
The variation in C. difficile yield from the three selective media may be attributed to 
differences in their content. Different concentrations of the selective agents D-cycloserine 
and cefoxitin have been recommended in order to balance diagnostic sensitivity and 
specificity of selective media (George et al., 1979; Levett, 1985). While the concentration of 
the selective agents in the CHR medium is not disclosed by the manufacturers, both the DCS 
and OXO media contained D-cycloserine and cefoxitin at the same final concentration (250 
µg/ml and 8 µg/ml respectively). These concentrations were introduced once it was 
established that some C. difficile strains were unable to grow when using the higher 
concentrations of the selective agents recommended in the original medium (Levett, 1985). 
However, this reduces the specificity of the medium, which is why heat- or alcohol-shock 
(a) (b) (c) 
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steps are often included prior to plating to enhance the yield of C. difficile bacteria and reduce 
the growth of contaminating bacteria. The resistant C. difficile spores are able to survive this 
treatment, while vegetative cells are removed (Marler et al., 1992; Riley et al., 1987). Neither 
heat- nor alcohol-shock procedures were performed in the current study, which may explain 
the high level of contaminating growth on the DCS and OXO media. The addition of 
taurocholate to C. difficile selective media enhances spore germination (Wilson et al., 1982). 
While the content of the CHR media is not known, taurocholate was not added to the DCS 
and OXO media in the current study, which may explain why fewer C. difficile isolates were 
obtained from these two media. The CHR media has been shown to be specific enough to 
isolate C. difficile cells directly from stool and this was again the case in the current study 
(Boseiwaqa et al., 2013; Carson et al., 2013). A recent media comparative study included the 
CHR medium and three other selective media. A Cycloserine-cefoxitin egg yolk agar 
(CCEY) was reported as being the most sensitive in the detection of C. difficile spores, 
followed by the CHR medium, which also had the best recovery rate of vegetative cells from 
stool specimens (Lister et al., 2014). 
 
2.3.2 Toxigenic typing of C. difficile pure strains using PCR 
Multiplex PCR screening for the C. difficile species-specific tpi fragment and the toxin A and 
B genes was used to confirm the identity of the C. difficile strains isolated from the selective 
media. All isolates harboured the C. difficile species-specific tpi fragment of 230 bp (Figure 
2.2 a). PCR screening for toxin genes revealed three toxigenic-types: A+B+, A-B+ and non-
toxigenic A-B-. Representative examples of these are depicted in Figure 2.2 (a). Further 
toxigenic typing was done by screening for the binary toxin genes cdtA and cdtB (Figure 2.2 
b). These binary toxin genes were absent in the clinical isolates from Groote Schuur Hospital.  
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(a)        
    
(b)  
 
Figure 2.2 Representative gels showing toxigenic typing of C. difficile. (a) Multiplex PCR 
screening for tpi, tcdA and tcdB and (b) binary toxin genes cdtA and cdtB.  M, 100 bp DNA 
Molecular weight ladder. NTC, no DNA template control. C. difficile strain 709 is a toxigenic 
A+B+CDT+ strain, and was used as positive controls in both reactions.  
 
Toxigenic typing of C. difficile from Groote Schuur Hospital patients revealed an equal 
representation (47% each) of A+B+ and A-B+ strains among the 34 isolates (Table 2.5).  
C. difficile strains isolated from two stool specimens were identified as non-toxigenic type  
A-B- as only the tpi gene fragment was amplified (Figure 2.2 a). This represented 6% of the 
study group. None of the isolates harboured the binary toxin genes. 
  M        A+B+    A-B+     A-B-      NTC 
     M           CDT+        CDT-        NTC 
Full length tcdA (369 bp) 
tpi (230 bp) 
tcdB (160 bp) 
Truncated tcdA (110 bp) 
Primer dimers 
cdtB (510 bp) 
cdtA (375 bp) 
Primer dimers 
1 kb  
 
 
500 bp  
400 bp  
300 bp  
200 bp  




1 kb  
500 bp  
400 bp  
300 bp  
200 bp  
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Table 2.5 Prevalence of toxigenic-types among clinical isolates 
Toxigenic-type Prevalence Specimen 
A+B+CDT- 47% 
GSH6553 GSH9316 GSH4696 GSH2753 
GSH8033 GSH8162 GSH9173 GSH1858 
GSH2702 GSH1795 GSH5681 GSH9354 
GSH5291 GSH1588 GSH1239 GSH4115 
A-B+CDT- 47% 
GSH6999 GSH4693 GSH2529 GSH5567 
GSH5556 GSH5760 GSH4722 GSH3758 
GSH8043 GSH8880 GSH3235 GSH1983 
GSH1709 GSH1526 GSH2797 GSH0616 
A-B-CDT- 6% GSH0574 GSH0541  
 
The high proportion of A-B+ strains amongst the Groote Schuur Hospital clinical isolates is 
interesting. This phenomenon, has also been observed in Asia (Kim et al., 2008, 2010; King 
et al., 2015; Komatsu et al., 2003), but is not the case in North America and Europe where 
disease is primarily due to A+B+ strains (Labbé et al., 2008; Warny et al., 2005). However, 
the incidence of A-B+ strains is of clinical concern since they have caused outbreaks in these 
parts of the world (al-Barrak et al., 1999; Drudy et al., 2007b; Kuijper et al., 2001). These 
strains contain a deletion in the tcdA gene and, therefore, only produce functional toxin B and 
yet they have been reported to cause severe disease (Drudy et al., 2007b; Kim et al., 2008; 
Kuijper et al., 2001). The previous study conducted at Groote Schuur Hospital made use of 
an EI-based assay, which only detected toxin A. It can, therefore, be concluded that the A-B+ 
strains remained undetected by this assay method resulting in an under-representation of the 
actual C. difficile prevalence. This may explain the prevalence in the previous study as 
approximately half (9.2%) of that found in the current study (20%). It should be noted that 
this conclusion is based on the assumption that the prevalence and the strain pattern were 
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similar during the previous study. Subsequent to the findings of the study reported in this 
thesis, the diagnosis methodology of CDI at the hospital was updated and now includes tests 
that detect both toxin A and B (section 2.3.3).   
None of the 34 isolates in this study had the binary toxin genes, which were present in the 
A+B+ ribotype 027 control strain (Figure 2.2 b). These genes were amplified among strains 
isolated from the Vhembe district, South Africa: 1.7% and 4% of symptomatic patients 
showed evidence of harbouring A-B-CDT+ and A+B+CDT+ strains, respectively (Samie et 
al., 2008). The binary toxin has been associated with PCR ribotype 027 and 078 strains. This 
additional toxin stimulates excessive microtubule growth of enterocytes resulting in 
protrusions, which have been suggested to contribute towards increased disease severity. The 
0% prevalence of C. difficile containing binary toxin genes suggests that it is likely that none 
of the isolates belong to ribotype 027, but this requires further confirmation (Chapter 3). 
 
2.3.3 Evaluation of clinical diagnostic methods 
The performances of two enzyme immunoassay (EI)-based and two nucleic acid 
amplification tests (NAATs) were evaluated in diagnosing C. difficile at Groote Schuur 
Hospital. The performance of each of the tests was evaluated relative to the following 
criteria: Any stool specimen that grew C. difficile on the combination of selective media with 
confirmed detection of the C. difficile species-specific tpi and tcdB gene fragments by PCR 
was considered a true positive. The performance of each of the tests is summarised in Table 
2.6 as percentages, and the importance of the various parameters evaluated are discussed 
below. 
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Table 2.6 Performance of clinical diagnostic methods relative to true positives *  
 ImmunoCard MiniVidas GeneXpert Hain Lifescience 
Sensitivity (%) 37.5 50.0 90.6 87.5 
Specificity (%) 98.3 98.3 96.4 89.7 
Positive predictive 
value (%) 85.7 88.2 87.9 70.0 
Negative predictive 
value (%) 85.4 88.5 97.3 96.3 
* A true positive is a specimen that grew C. difficile on selective media and confirmed by detecting the  
C. difficile tpi and tcdB fragments by PCR. 
 
Sensitivity 
The sensitivity of a clinical test is its ability to accurately identify a true-positive specimen as 
positive (Lalkhen & McCluskey, 2008). A sensitivity of 37.5% is interpreted as the 
ImmunoCard only being able to identify 37.5% of the specimens that did, in fact, harbour 
toxin-positive C. difficile. This indicates that the ImmunoCard lacked the ability to effectively 
detect toxins A and B immunologically in the stool specimens and, therefore, provided an 
under-representation of the intestinal presence of C. difficile within the hospital. The 
MiniVidas, another EI-based method, also had a low sensitivity and was able to detect toxins 
in only half of the C. difficile positive specimens. In contrast the NAATs had high sensitivity 
values, with the Hain Lifescience and GeneXpert being able to positively identify the 
majority (87.5 % and 90.6%, respectively) of the specimens harbouring C. difficile. These 
results suggest that the EI-based assays are not as effective in identifying C. difficile positive 
stool specimens as the NAATs. Several studies have also evaluated the validity of these two 
EI-based methods and have established that they are not as sensitive in detecting toxins A and 
B (Peterson et al., 2011; Planche et al., 2008). Studies comparing EI-based assays to NAATs 
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have also calculated a higher sensitivity for NAATs (Eastwood et al., 2009; Hernández-
Rocha et al., 2013; Swindells et al., 2010). The GeneXpert had the highest sensitivity (Table 
2.6) suggesting that it is the most effective test of the clinical diagnostic methods investigated 
by this study. 
The low detection rate of the EI-based assays could possibly be influenced by the dilution of 
stool toxin by the increased volume of stool due to diarrhoea, or to degradation of toxins by 
the time the assay was performed. Another plausible reason for a false-negative result is that 
C. difficile may not be producing toxins in the intestine when the stool specimen was 
collected. Faecal bacterial load can also affect the performance of a detection method. It has 
been proposed that tests with a high sensitivity are able to detect a lower faecal bacterial load. 
A few studies have investigated this and reported that specimens identified as positive by 
only a PCR-based method had the lowest bacterial load, while those identified by both PCR 
and EI-based methods had a significantly higher bacterial load (Dionne et al., 2013; Leslie et 
al., 2012). 
The detection of free toxins within stool specimens compared to PCR detection of toxigenic 
 C. difficile with the potential to produce toxins has raised debate (Su et al., 2013). C. difficile 
toxins are the main virulence factors of CDI, but the actual proteins cannot be detected by 
NAATs. While NAATs have a high sensitivity, they are less specific as they do not 
differentiate between active CDI and patients that simply harbour the bacterium and have 
diarrhoea caused by alternative agents. Specimens determined as positive by the GeneXpert, 
but negative by the EI-based assays may contain toxigenic C. difficile strains that are not 
actively producing toxins at the time of sampling. Alternatively, toxins may be produced, but 
the EI-based assays are not sensitive enough to detect them. This warrants the investigation 
of toxin activity to determine whether C. difficile detected by GeneXpert is responsible for 
disease in symptomatic patients. To overcome this two-step and three-step diagnostic 
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algorithms have been proposed and published (Bamber et al., 2012; Goldenberg et al., 2010). 
This involves combining currently available diagnostic methods where the first test is 
employed for initial screening and the second and/or third test to confirm the diagnosis. 
Improved clinical performances have been reported using these algorithms; however, they 
can cost more and are more time consuming.   
Specificity 
Specificity is the ability of a clinical test to accurately identify a true-negative specimen as 
negative (Lalkhen & McCluskey, 2008). A low specificity would be the result of a high 
number of false-positive results. Both EI-based assays had high specificities, reflecting a low 
proportion of false positive results. The low sensitivity and high specificity of the EI-based 
assays in this study compares to the values reported by previous studies when compared to 
the toxigenic culture or cell culture cytotoxicity neutralisation assay methods (Eastwood et 
al., 2009; Hernández-Rocha et al., 2013; Swindells et al., 2010). The Hain Lifescience test 
had the lowest specificity value (89.7%), which indicates that this test most often identified 
non-C. difficile targets in the stool specimen as C. difficile positive. Despite the lower 
specificity of the NAATs, they are rapid and their detection of toxigenic C. difficile is useful 
in the prevention of nosocomial transmission and the implementation of infection control.   
Positive and negative predictive values 
The positive predictive value (PPV) of a diagnostic test is the likelihood that a patient does 
have the disease given that the test result is positive, while the negative predictive value 
(NPV) is the likelihood that a patient is disease-free given that the test result is negative. The 
PPV and NPV vary depending on the prevalence of the disease, and are useful to clinicians 
by giving an indication of a given test’s usefulness in a particular population, while 
sensitivity and specificity evaluates the detection capacity alone. Of the four diagnostic tests, 
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the Hain Lifescience test had the lowest PPV (70.0%), whereas the other tests had similar 
PPVs (85.7-88.2%) (Table 2.6). Therefore, in this particular population, the Hain Lifescience 
test has the highest risk of producing a false-positive among the four tests. The GeneXpert 
and Hain Lifescience tests had the highest NPV (97.3% and 96.3% respectively), which 
provides clinicians with the most confidence in these tests regarding the correct identification 
of CDI disease-free patients.  
The low clinical sensitivity values of the EI-based assays suggest that they are not ideal as a 
stand-alone detection method at Groote Schuur Hospital, and should be replaced by a more 
sensitive one, such as a NAAT, for rapid and reliable diagnosis. Overall, the GeneXpert 
performed the best. It had the highest clinical sensitivity value, PPV and NPV, and it had a 
high specificity value; which all provides confidence in its results in the local setting. In 
addition, the GeneXpert results were in agreement with the PCR analysis targeting the tpi, 
tcdB and cdtA genes. It should be noted, however, that the GeneXpert is designed to 
presumptively ideally identify isolates belonging to the ribotype 027 clade, although it can 
detect the presence of other ribotypes as well. In addition, the genetic markers targeted by the 
GeneXpert to identify a ribotype 027 isolate are not only associated with this clade. 
Therefore, the GeneXpert is not specific to ribotype 027 isolates. Despite these drawbacks, 




In conclusion, C. difficile was present in a significant proportion of symptomatic patients 
attending Groote Schuur Hospital during the study period. NAATs were more sensitive for 
detecting C. difficile than the EI-based tests and the results of these analyses have encouraged 
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the Microbiology Laboratory at the NHLS to adopt the GeneXpert for clinical diagnosis of 
CDI. While the NAATs only detect the presence of the various C. difficile genes future work 
should also establish whether the C. difficile isolates have the potential to actually produce 
toxins in order to confirm that the C. difficile detected by the NAATs is capable of causing 
disease.    
The high proportion of toxigenic-type A-B+ strains in this study group is interesting and 
could be indicative of strain transmission between patients. However, in order to assess this, 
further genotyping methods are necessary to identify exactly which C. difficile strains are 
present amongst the study population. PCR ribotyping and multilocus variable-number 
tandem-repeat analysis (MLVA) are techniques that have been used previously to examine  
C. difficile strain diversity (van den Berg et al., 2007; Stubbs et al., 1999). These aspects 
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Various C. difficile strains have emerged which can cause disease. Genotyping methods 
developed for C. difficile have allowed the monitoring of the spread of the various strains, 
which may reach epidemic levels. In this study, three genotyping methods were used to 
identify C. difficile clinical isolates from patients at Groote Schuur Hospital and determine 
their relatedness. PCR ribotyping identified twelve different ribotypes among the clinical 
isolates. All the toxigenic A-B+ isolates belonged to PCR ribotype 017, which was the 
predominant ribotype (47%). Ribotypes 001 (14%), 015 (9%) and SE108 (6%) were also 
identified, as well as one isolate of each of the following ribotypes: 002, 012, 056, SA1, SE9, 
SE19m, SE21e and SE23a. Genotyping based on sequencing of the tcdC gene grouped the 
isolates into four tcdC genotypes, with PCR ribotype 017 isolates forming a separate clade. 
MLVA allowed further subtyping of isolates within a single ribotype. Isolates of the same 
ribotype were clustered together and ribotype 017 isolates again formed a separate clade. The 
predominance of ribotype 017 among the clinical isolates and the clustering of these isolates in 
separate clades by tcdC and MLVA genotyping suggest that this group is significantly different 
from the others and that there may be selective pressure promoting the high prevalence of this 




Several different strain types of C. difficile that cause disease have emerged and have reached 
epidemic proportions in many parts of the world (as reviewed in Chapter 1). In order to 
identify and monitor strains of concern, various molecular typing methods for C. difficile have 
been developed. These include restriction-based methods such as pulsed-field gel 
electrophoresis (PFGE) and restriction endonuclease analysis (REA) (Clabots et al., 1993; Gal 
et al., 2005), amplification-based methods such as amplified fragment length polymorphism 
(AFLP), arbitrarily primed PCR (AP-PCR) and PCR ribotyping (Klaassen et al., 2002; 
McMillin & Muldrow, 1992; Stubbs et al., 1999), and sequence-based methods such as 
multilocus sequence typing (MLST) and slpA typing (Griffiths et al., 2010; Kato et al., 2010). 
While these methods have improved the monitoring of outbreaks and transmission, and helped 
to reduce the incidence of CDI, many of them require specialised expertise and/or equipment, 
and inter-laboratory comparisons are often difficult. 
PCR ribotyping is most frequently employed in Europe, and more recently in the USA, and an 
extensive PCR ribotype database has been generated allowing the identification of over 400 
PCR ribotypes (Cardiff-European Centre for Disease Prevention and Control (ECDC) 
collection). Ribotyping involves PCR amplification of the 16S-23S rRNA gene intergenic 
spacer sequences and the resulting band patterns are visualised on agarose gels or analysed by 
capillary gel electrophoresis and compared to a web-based database such as Webribo (Indra et 
al., 2008; Stubbs et al., 1999). Two different sets of primers have been proposed (Bidet et al., 
1999; Stubbs et al., 1999), with the O’Neil primers described by Stubbs et al., (1999) having a 
reportedly higher discriminatory power (van den Berg et al., 2004). 
With the aid of genotyping techniques, it has been observed that the distribution of C. difficile 
strain types has varied temporally and geographically. In the last decade, PCR ribotype 027, 
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also referred as NAP1 or BI, has been linked to the increase in the number of CDI cases and 
outbreaks in North America and Europe (Labbé et al., 2008; McDonald et al., 2005; Smith, 
2005). More recently, ribotype 027 has also been reported to cause disease in further European 
countries, Asia, Australia and Latin America (Bacci et al., 2009; Baldan et al., 2010; Cheng et 
al., 2009; Kato et al., 2007; Lachowicz et al., 2014; Oleastro et al., 2014; Quesada-Gómez et 
al., 2010; Riley et al., 2009). Other PCR ribotypes reaching high proportions and/or causing 
outbreaks include ribotype 078 (Goorhuis et al., 2008; Weber et al., 2013); ribotype 001 
(Borgmann et al., 2008; Stubbs et al., 1999); and ribotype 017 in North America (Tenover et 
al., 2011), Europe (Dobreva et al., 2013; Pituch et al., 2011), and frequently in many Asian 
countries (Hawkey et al., 2013; Lee et al., 2014; Ngamskulrungroj et al., 2015).  
As an addition to PCR ribotyping, the sequences of numerous genes, including the tcdC gene, 
which encodes a putative negative regulator of toxin production, have been used for cluster 
analysis of C. difficile to determine the relatedness of strains belonging to different PCR 
ribotypes (Kurka et al., 2014). Several polymorphisms in the tcdC gene have been identified 
and found to be associated with various PCR ribotypes (Curry et al., 2007; Spigaglia & 
Mastrantonio, 2002). 
In order to investigate closely related strains, thereby allowing the determination of strain 
transmission during an outbreak, additional genotyping methods of a higher discriminatory 
power are required. Multilocus variable-number tandem-repeat analysis (MLVA) and whole 
genome sequencing (WGS) have been previously used for this purpose (van den Berg et al., 
2007; Cairns et al., 2015; Eyre et al., 2013a). WGS can be used to distinguish C. difficile 
strains based on single-nucleotide variants between the isolates. MLVA involves PCR 
amplification and distinguishes C. difficile strains based on the varying sizes of short tandem 
repeats distributed throughout the genome (van den Berg et al., 2007; Marsh et al., 2006). 
MLVA is a cheaper method than WGS and does not require the extensive bioinformatics 
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analysis required for the latter. Moreover, the technique has been shown to be almost as 
discriminatory as WGS (Eyre et al., 2013b). 
Monitoring the spread and emergence of C. difficile by identifying strains is important for the 
implementation of effective infection control. By determining the epidemiology of circulating 
strains, targeted interventions can be applied when an epidemic strain is identified. When 
employed in conjunction with national surveillance schemes, accurate strain typing and 
monitoring have previously been associated with a decline in the prevalence of epidemic 
strains (Kanerva et al., 2013; Wilcox et al., 2012).  
Prior to this study, the types of C. difficile infecting patients at Groote Schuur Hospital, and 
potentially causing disease, were not known. Therefore, the aim of the work reported in this 
chapter was to apply molecular genotyping techniques to determine the identity and 
distribution of C. difficile PCR ribotypes. The genetic relatedness of the clinical isolates to one 
another and to international C. difficile reference strains was determined based on the tcdC 
gene sequence and multilocus variable-number tandem repeats distributed throughout the 
genome. 
 
3.2 Materials and Methods 
3.2.1 Bacterial strains and plasmids 
C. difficile strains listed in Table 3.1 were used as control strains for genotyping. The cloning 






Table 3.1 C. difficile reference strains used for genotyping analysis 
Strain Ribotype Reference/Origin 
C. difficile 709 Ribotype 027 Gift from Prof Andrej Weintraub, 
Karolinska Institute, Stockholm, 
Sweden C. difficile 728 Ribotype 078 
C. difficile 630 Ribotype 012 
Gift from Prof Brendan Wren, 
London School of Hygiene and 
Tropical Medicine, London, UK 
C. difficile CD305 Ribotype 023 
C. difficile M120 Ribotype 078 
C. difficile M68 Ribotype 017 
C. difficile CF5 Historic ribotype 017 
C. difficile CD196 Historic ribotype 027 
C. difficile R20291 Hyper-virulent ribotype 027 
 
3.2.2 Genomic DNA extraction  
Genomic DNA (gDNA) was extracted from 16 hour cultures grown in BHI broth (Chapter 2) 
using the ISOLATE II Genomic DNA Kit (Bioline). A pre-lysis step of the broth culture, using 
200 µl resuspension buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8) containing lysozyme (2% 
w/v), proteinase K (1% v/v) and Triton X-100, was included. A total of 100 ng gDNA was 
used as template for the MLVA and tcdC PCRs. PCR ribotyping made use of DNA template 
obtained by cell lysis as described in Chapter 2 (section 2.2.4). 
3.2.3 PCR ribotyping 
PCR ribotyping was performed using previously described primers (Stubbs et al., 1999). 
Genomic DNA of C. difficile 709 and 728 were used as positive PCR controls. PCRs were 
performed in a 100 µl reaction volume containing 0.5 µM of each primer (5'-
CTGGGGTGAAGTCGTAACAAGG-3' and 5'-GCGCCCTTTGTAGCTTGACC-3'). The 
reactions were denatured at 95ºC for 5 min, and then subjected to 35 cycles of 94ºC for 1 min, 
55ºC for 1 min and 72ºC for 2 min, followed by a final extension at 72ºC for 5 min. Reactions 
were performed using a Primus 25 thermo cycler (PEQLAB). PCR products were concentrated 
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by heating at 75ºC for 105 min and resolved by electrophoresis on a 3% agarose gel stained 
with ethidium bromide (Stubbs et al., 1999). Banding patterns were compared visually to a 
laboratory database of known PCR ribotypes. Isolates with ribotype patterns that could not be 
identified using this database were submitted to Andrej Weintraub at Karolinska Institute for 
further analysis. PCR ribotypes annotated with ‘SE’ were identified using a Swedish library, 
and remaining ribotypes were identified according to the Cardiff-ECDC nomenclature. 
3.2.4 Amplification and sequencing of the tcdC gene 
The full-length tcdC gene of all toxigenic clinical isolates was amplified using previously 
described primers (Spigaglia & Mastrantonio, 2002). PCRs were performed in 25 µl reaction 
volumes containing 0.3 µM of each primer (5'-TTAATTAATTTTCTCTACAGCTATCC-3' 
and 5'-TCTAATAAAAGGGAGATTGTATTATG-3') in Kapa HiFi HotStart ReadyMix (Kapa 
Biosystems). The reactions were denatured at 95ºC for 5 min, and then subjected to 25 cycles 
of 98ºC for 20 s, 50ºC for 30 s and 72ºC for 80 s, followed by a final extension at 72ºC for  
5 min. PCR products were cloned into the pJet1.2 vector (Thermo Scientific) and transformed 
into competent E. coli JM109 using standard protocols (Sambrook et al., 1989). Plasmid DNA 
was extracted using the Plasmid DNA Extraction Kit (BioFlux) according to the 
manufacturer’s instructions, and the presence of insert confirmed by both PCR using the 
pJet1.2F/R primer set and by restriction mapping. DNA sequencing was performed by 
Macrogen Inc., Seoul, South Korea. Nucleic acid sequences were analysed using DNAMAN 
(v. 4.13) and compared to the National Centre for Biotechnology Information (NCBI) database 
using the BLAST algorithm (Altschul et al., 1997). Published tcdC sequences for strains 630, 
CF5, M68, CD305, CD196, R20291 and M120 were obtained from the NCBI database. 
Nucleic acid sequences were aligned and a dendrogram was constructed using the Neighbour 




3.2.5 Multilocus variable-number tandem-repeat analysis (MLVA) 
The clinical isolates and the reference strains (Table 3.1) were typed using MLVA as 
previously described (van den Berg et al., 2007). PCR amplifications of seven loci, designated 
A6, B7, C6, E7, F3, G8 and H9 (Table 3.2), were performed as three separate duplex reactions 
(A6 – H9, B7 – F3, and C6 – E7) and one single reaction (G8). PCRs were performed in a 50 µl 
reaction volume containing Kapa HiFi HotStart ReadyMix (Kapa Biosystems) and 0.2 µM of 
each primer. The reactions were denatured at 95ºC for 5 min, and then subjected to 35 cycles 
of 98ºC for 20 s, 51ºC for 30 s and 72ºC for 30 s, followed by a final extension at 72ºC for  
10 min. 
 
Table 3.2 Primers used for C. difficile MLVA genotyping (van den Berg et al., 2007) 





























*The numbers written in subscript indicate the size of the repeat motif of each loci targeted. 
 
The forward primer for each marker was labelled on the 5' end with either  
6-carboxyfluorescein (FAM), hexachlorofluorescein (HEX), 5-tetrachloro-fluorescein (TET) or 
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Cyanine 5 (Cy5) (Table 3.2).  PCR fragments were analysed using multi-coloured capillary gel 
electrophoresis on an ABI 3130xl genetic analyser, with a ROX500 marker as an internal size 
standard for each sample. The size of each locus was determined using Peak Scanner version 
1.0 software (Applied Biosystems). The repeat numbers for each locus were calculated 
manually and the isolate profiles compared to each other using the Manhattan coefficient to 
construct a minimum spanning tree in BioNumerics version 7.1 software (Applied Maths, 
Kortrijk, Belgium). Isolates with a summed tandem repeat difference (STRD) of ≤ 2 across the 
seven loci were identified as genetically related. 
 
3.3 Results and Discussion 
3.3.1 Typing of C. difficile isolates by PCR ribotyping 
This study used PCR ribotyping to identify the C. difficile clinical isolates and compare them 
to international strains. A total of twelve PCR ribotypes were identified among the 34 clinical 
isolates. The ribotype distribution is summarised in Figure 3.1 (a) and representative gels of 
PCR product pattern for each ribotype are depicted in Figure 3.1 (b). The PCR product patterns 
correspond to the Swedish and Cardiff databases. PCR ribotype 017 was the predominant 
strain (47%), followed by ribotypes 001 (14%), 015 (9%) and SE 108 (6%). The remaining 
isolates each belonged to a different ribotype: 002, 012, 056, SA1, SE9, SE19m, SE21e and 
SE23a (3% each). PCR ribotype 027 was included as a reference PCR product (Figure 3.1 b); 
however, none of the clinical isolates had banding patterns identical to this ribotype. All the  
A-B+ isolates belonged to ribotype 017. The non- toxigenic isolates, GSH0574 and GSH0541, 
belonged to ribotypes SE9 and SA1, respectively. The A+B+ isolates belonged to the 






                
                  
Figure 3.1 PCR ribotyping. (a) Distribution of PCR ribotypes among the 34 clinical isolates. 
(b)  Representative gel images showing examples of the PCR ribotype banding patterns.  
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This study is the first to identify PCR ribotypes of C. difficile within South Africa; therefore, a 
comparison to other sites in the country cannot be made. Approximately half of the isolates, all 
toxigenic-type A-B+, belonged to PCR ribotype 017. Ribotype 017 isolates are typically 
characterised by a 1.8 kb deletion in the tcdA gene, but are still capable of causing severe 
disease (Alfa et al., 2000). Many ribotype 017 isolates have also been characterised as resistant 
to multiple antimicrobials (Kim et al., 2012b; Pituch et al., 2011). It is difficult to accurately 
determine the prevalence of ribotype 017 strains in other parts of the world on the basis of 
toxigenic-types alone since not all A-B+ strains belong to ribotype 017 and non-017 A-B+ 
strains have been reported in Asia (Rupnik et al., 2003). In addition, several published studies 
from sites in Asia report a high prevalence of A-B+ strains, but they do not always specifically 
identify the ribotype of these isolates (Chia et al., 2013; Rupnik et al., 2003). However, studies 
that report the PCR ribotype have identified ribotype 017 as the leading strain at hospitals in 
Korea, China, Poland and Bulgaria (Dobreva et al., 2013; Hawkey et al., 2013; Kim et al., 
2010a, b; Pituch et al., 2011). The epidemic proportions that this ribotype has reached in some 
parts of the world and the high prevalence of this ribotype reported by this study suggest it may 
have the potential to cause significant problems at the Groote Schuur Hospital study site. 
PCR ribotype 001 was the second most prevalent ribotype among the clinical isolates. This 
ribotype has become frequently isolated in Europe and North America (Bauer et al., 2011; 
Borgmann et al., 2008; Cheknis et al., 2009; Stubbs et al., 1999). The worldwide prevalence of 
ribotype 001 has reduced in recent years; however, this is the ribotype that is most often 
reported to display reduced susceptibility to metronidazole, which is the antimicrobial 
recommended for first-line treatment of CDI. Continued molecular typing of South Africa 
isolates and determination of antimicrobial susceptibility is necessary to determine whether this 
trend is also observed locally.   
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PCR ribotypes 002, 012, 015 and 056 were of a low prevalence in this study. These ribotypes 
have been isolated in Europe, but also at lower frequencies (Bauer et al., 2011). The hyper-
virulent ribotypes 027 and 078 were not identified among any of the clinical isolates from 
GSH. These results are in agreement with the absence of binary toxin genes in the isolates, 
which are characteristic of these two ribotypes, and in agreement with the results of GeneXpert 
(Cepheid), which did not presumptively identify ribotype 027 in any of the stool specimens 
(Chapter 2). Thus, the prevalence of PCR ribotypes in this study is similar to some Asian 
hospitals where there is a high prevalence of ribotype 017 and scarcity of ribotype 027, relative 
to the high proportions of the latter in other parts of the world (Cheknis et al., 2009; Hawkey et 
al., 2013; Labbé et al., 2008).  
The disadvantage of PCR ribotyping is the need to compare and differentiate banding patterns 
visually, under identical conditions and preferably on the same gel. This requires inter-
laboratory exchange of the actual bacterium or gDNA. To overcome this problem, capillary gel 
electrophoresis-based PCR ribotyping has been developed, for which a web-based database has 
been created (Indra et al., 2008). While the Cardiff database has grown to over 400 PCR 
ribotypes, there remain several ribotypes yet to be identified and, therefore, the identification of 
some strains was not always possible in this study. Ribotypes SE9, SE19m, SE21e, SE23a and 
SE108 were identified according to a library at the Karolinska Institute in Sweden (with thanks 
to Dr Andrej Weintraub). One isolate could not be identified by comparative analysis with any 
other available control and was assigned a temporary PCR ribotype, SA1, until the identity is 




3.3.2 Genotyping based on the tcdC gene 
Molecular genotyping based on the tcdC gene was performed to differentiate toxigenic  
C. difficile isolates and determine the association between tcdC genotype and PCR ribotype. 
Four different tcdC genotypes were identified among the clinical isolates, all of which have 
been reported previously (Curry et al., 2007). When aligned to one another and plotted as a 
dendrogram, the clinical isolates were grouped into four clades with ribotypes 027 and 078 
control strains creating an additional two clades (Figure 3.2). Ribotypes 002, 015, 056, SE19m 
and SE108 grouped together and belonged to the tcdC-0, or the wild type genotype. 
Ribotype 001 belonged to tcdC-sc3, which is characterised by a single nucleotide substitution 
at position 148 leading to an alanine to serine change in the translated protein. Ribotypes 012, 
SE21e and SE23a belonged to tcdC-sc9, characterised by a single nucleotide substitution at 
position 21 leading to a glutamate to aspartate change. Ribotype 017 diverged from the A+B+ 
clinical isolates and belonged to tcdC-sc7, characterised by five different nucleotide 
substitutions, of which two lead to amino acid changes in the translated protein. None of the 
clinical isolates were grouped with the ribotype 023, 027 or 078 control strains, which belong 
to the tcdC-sc16, tcdC-sc1 and tcdC-A, respectively, which are characterised by nonsense 
mutations that lead to truncated proteins (Curry et al., 2007; Spigaglia & Mastrantonio, 2002). 
The two non-toxigenic isolates belonging to ribotypes SE9 and SA1, respectively, do not 




Figure 3.2 A Dendrogram based on the nucleotide sequence of the tcdC gene of  
C. difficile constructed using the Neighbour Joining method. The ribotype is indicated in 
brackets. Numbers at the branch points represent the bootstrap values. The tcdC genotype is 
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Previously published studies report that C. difficile differentiates into five clades based on 
MLST and whole genome sequencing (Dingle et al., 2011a; Griffiths et al., 2010; Stabler et 
al., 2012). Clade 1 is heterogeneous consisting of ribotypes 001, 002, 012, 015, 056 and others. 
Clade 2 consists of ribotype 027, clade 3 of ribotype 023, clade 4 of ribotype 017, and clade 5 
of ribotype 078. In this study, isolates differentiated based on tcdC nucleotide sequences 
clustered in a similar manner. The clustering of isolates belonging to the same PCR ribotype in 
the tcdC dendrogram correspond with published studies that show that PCR ribotype is not 
only a reflection of variation in 16S-23S rRNA intergenic spacer sequences but also a 
reflection of differences in the tcdC sequence (Kurka et al., 2014). A published study 
demonstrated this correlation between sequence diversity of the tcdC gene, as well as other  
C. difficile conserved genes, and PCR ribotype (Kurka et al., 2014), thus demonstrating that 
PCR ribotyping as a suitable method for grouping C. difficile. However, while tcdC genotyping 
groups isolates belonging to the same ribotype together, typing based on this single gene does 
not differentiate isolates further within a PCR ribotype, demonstrating tcdC genotyping as a 
typing method of a low discriminatory power. A more discriminatory molecular genotyping 
technique was, therefore, attempted. 
 
3.3.3 Subtyping by MLVA 
MLVA, a highly discriminatory molecular typing method, was performed to subtype all the 
isolates further (Killgore et al., 2008). Amongst the 34 clinical isolates 31 unique MLVA types 
were observed (Figure 3.3). Seven control strains belonging to ribotypes 012, 017, 023, 027 
and 078 were included in the analysis and generated an additional seven MLVA types. Isolates 
belonging to the same ribotype clustered together. The sixteen clinical isolates belonging to 
ribotype 017 formed a distinct clade differentiating them from the toxigenic A+B+ strains.  
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Figure 3.3 Minimum spanning tree representation of MLVA data for C. difficile isolates. Unique MLVA types are repesented by indvidual 
circles and the size of the circle represents the number of isolates per MLVA type. Numbers between the circles represent the STRDs between 
isolates and isolates with a STRD ≤ 2 are linked by a dotted line. The colour of the circle represents the PCR ribotpe. Circles labelled C represent 
published strains and serve as controls in this analysis. The grey shading is indicative of MLVA types belonging to the same tcdC genotype. The 
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A group of two isolates and a group of three isolates were indistinguishable by MLVA, as 
represented by enlarged circles in Figure 3.3, and were regarded as the same bacterial clone. 
Therefore, a group of two and a group of three patients were infected with the same  
C. difficile strain, respectively. In addition, two groups of two isolates, encircled by a dotted 
line in Figure 3.3, had a summed tandem repeat difference of (STRD) of one and two, 
respectively. Isolates having a STRD of ≤ 2 have previously been regarded as genetically 
related (van den Berg et al., 2007) and may be indicative of transmission between these two 
sets of patients. MLVA showed genetic relatedness and differentiation among isolates that 
was not apparent by PCR ribotyping. 
Interestingly, some ribotype 001 isolates were more closely related to ribotype SE21e than to 
one another. In addition, two ribotype 015 isolates, GSH1795 and GSH9173, were more 
closely related to ribotype SE108 than the third ribotype 015 isolate, GSH4696. The 
clustering of ribotypes can be improved using the extended MLVA (eMLVA) approach 
(Manzoor et al., 2011), which involves increasing the number of targeted loci to fifteen. This 
method has been shown to further differentiate within a single ribotype and to create tighter 
ribotype clusters with greater STRDs between ribotype clusters. However, the cost of 
increasing the number of loci can be prohibitively expensive, due to the large numbers of 
labelled primers and extra capillary gel analyses required. In this study, the STRDs between 
different ribotypes were as low as five (Figure 3.3), while eMLVA generated STRDs ≥ 23 
between different ribotypes (Manzoor et al., 2011). Alternatively, WGS sequencing can be 
used. A recent study reported three diverging sub-lineages of ribotype 017 strains using WGS 
(Cairns et al., 2015).  
The clustering of ribotypes based on MLVA is similar to tcdC genotyping (Figure 3.2) as 
represented by the shaded areas in Figure 3.3 with the exception of ribotypes SE19m and 
SE23a, which belonged to tcdC-0 and tcdC-sc9, respectively. Other than these exceptions, the 
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data generated by MLVA and tcdC genotyping are in agreement. The clustering of tcdC 
genotypes could also perhaps be improved by eMLVA. 
MLVA can be used to investigate C. difficile transmission and outbreaks (Dingle et al., 
2011a; Eckert et al., 2011; Goorhuis et al., 2009). The data generated by MLVA can be used 
in conjunction with information such as hospital admission or the ward a patient resided in to 
demonstrate patient-to-patient transmission and determine whether MLVA types are 
restricted to wards. Alternatively, information such as the date of admission and date of 
specimen collection could be used to track the spread over time. A published study using 
eMLVA, reported smaller STRDs between isolates from the same time period (Manzoor et 
al., 2011). In this study, a group of three ribotype 017 isolates, GSH6999, GSH3758 and 
GSH8043, were of the same MLVA type (Figure 3.3); however; GSH6999 was isolated 
approximately five months prior to the other two isolates. In addition, GSH3758 and 
GSH8043 were isolated two days apart, however, from different wards. This is suggestive of 
this strain type being able to persist in the hospital. 
 
3.4 Conclusion 
This is the first study to identify the PCR ribotypes of C. difficile in South Africa providing a 
platform for future epidemiological studies. In general, PCR ribotyping, tcdC genotyping and 
MLVA genotyping agreed with one another even though the typing methods rely on different 
targets in the genome. PCR ribotyping identified twelve different ribotypes. With the 
exception of ribotype SA1, which could not be successfully identified using the available 
libraries, the remaining eleven PCR ribotypes identified were not novel. Genotyping based on 
the tcdC gene grouped the isolates according to four genotypes with ribotype 017 isolates 
forming a separate clade. MLVA genotyping was able to subtype isolates belonging to the 
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same PCR ribotype and genetic diversity was reflected by PCR ribotyping with ribotype 017 
isolates forming a distinct clade.  
The predominance of ribotype 017 suggests that it may be more virulent and/or selected for 
by antimicrobial or environmental pressure. The clustering of ribotype 017 in a single and 
entirely separate clade based on tcdC and MLVA genotyping indicates that this strain is 
different. Published studies have described ribotype 017 as a high-level and multi-drug 
resistant pathogen (Davies et al., 2014; Drudy et al., 2007a; Kim et al., 2012a). In this study, 
the antimicrobial resistance of the Groote Schuur Hospital isolates was, therefore, 
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C. difficile displays resistance to various antimicrobials, and their use can, therefore, result in 
an increased risk of developing CDI. Despite the evolving resistance profiles of some  
C. difficile strain types, metronidazole (MET) and vancomycin (VAN) remain the current 
treatments of choice for CDI in South Africa. In this study, antimicrobial susceptibility 
profiles for each of the clinical isolates were determined. Etests showed that all the clinical 
isolates were sensitive to both MET and VAN, although some ribotype 017 isolates displayed 
reduced susceptibility to MET. None of the strains displaying reduced susceptibility to MET 
harboured the previously characterised nim gene resistance determinants. Eleven isolates 
(32%), all belonging to ribotype 017, were resistant to moxifloxacin (MOX) and had a 
Thr82Ile amino acid substitution in GyrA. Four isolates (12%), also ribotype 017, displayed 
reduced susceptibility to MOX and had an Asp426Asn amino acid substitution in GyrB. 
Sixteen isolates (47%), primarily ribotype 017, were highly resistant to erythromycin (ERY) 
(MIC ≥ 256 µg/ml) and harboured the ermB gene, which is known to contribute towards ERY 
resistance. Another two isolates (6%) were resistant to ERY (48 µg/ml), but did not harbour 
the ermB gene. Disc diffusion analysis revealed potential resistance to clindamycin, 
ciprofloxacin, cefotaxime, ceftriaxone and tetracycline, and ribotype 017 strains showed a 
trend towards multi-drug resistance. The resistance profile of the ribotype 017 isolates may 




A major risk factor for developing CDI is the use of broad-spectrum antimicrobials (Baxter et 
al., 2008), which disrupt the enteric microbiota allowing the overgrowth of resistant  
C. difficile strains (Sullivan et al., 2001). Clindamycin, penicillin, cephalosporins, and 
fluoroquinolones have mostly been implicated in the development of CDI and outbreaks of 
the disease (Biller et al., 2007; Dubberke et al., 2015; Johnson et al., 1999; Kim et al., 2012a; 
Pépin et al., 2005). Different levels of resistance to these antimicrobials in C. difficile have 
been reported worldwide.  
Clindamycin is a macrolide-lincosamide-streptogramin B (MLSB) agent, which inhibits 
protein synthesis by targeting the 23S rRNA gene (Tenson et al., 2003). Resistance to MLSB 
agents in C. difficile is usually mediated by an erythromycin ribosomal methylase (ermB) 
gene, the product of which dimethylates the 23S rRNA gene (Farrow et al., 2001). 
Fluoroquinolones inhibit DNA replication by interacting with DNA gyrase subunits A and B 
(Hooper, 1999). Resistance is associated with mutations in the gyrA and gyrB genes resulting 
in amino acid substitutions in the encoded proteins (Dridi et al., 2002; Drudy et al., 2006). 
Despite the evolving resistance profile of C. difficile, metronidazole or vancomycin remain 
the preferred treatment options for CDI. However, recent published studies report reduced 
susceptibility to metronidazole in some C. difficile strains, and reports of metronidazole or 
vancomycin resistance have also been published (Baines et al., 2008; Brazier et al., 2001; 
Chia et al., 2013; Peláez et al., 2008). The developing trend towards reduced susceptibility to 
these agents indicates that the monitoring of in vitro antimicrobial susceptibility is important.  
In B. fragilis, resistance to metronidazole is, in certain cases, associated with the presence of 
various nitroimidazole genes (nimA-J) (Gal & Brazier, 2004; Haggoud et al., 1994; Husain et 
al., 2013). These nim genes encode nitroreductases, which inactivate metronidazole. A 
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published study that made use of “universal” primers targeted to conserved sequences in the 
B. fragilis nimA-H genes reported the presence of these genes in other species including one 
strain of Clostridium bifermentans (Lubbe et al., 1999). However, nim homologues in  
C. difficile, have not yet been reported (Brazier et al., 2001; Peláez et al., 2008). A role for 
nim genes in C. difficile has, therefore, not yet been conclusively established and the exact 
mechanism of metronidazole resistance has yet to be determined.  
Prior to this study, C. difficile strains had not been isolated from patients at Groote Schuur 
Hospital and so the antimicrobial resistance in this bacterium had also not been determined. 
The aim of the work presented in this chapter was to determine the antimicrobial 
susceptibility profiles of the previously identified C. difficile isolates, to examine a potential 
association of resistance with PCR ribotype, and to identify the possible underlying genetic 
resistance mechanisms of the resistant isolates. 
 
4.2 Materials and Methods 
4.2.1 Bacterial strains 
The Groote Schuur Hospital C. difficile isolates listed in Table 2.5 (Chapter 2) and the  
C. difficile reference strains listed in Table 3.1 were included for antimicrobial susceptibility 
characterisation. However, the gyrA and gyrB genes from only C. difficile isolates displaying 
some resistance to moxifloxacin, as well as three selected sensitive isolates, were sequenced. 
C. difficile strains listed in Table 4.1 were used as controls, and B. fragilis strains were used 




Table 4.1 Control strains  
Strain Genotype/phenotype Reference/source 
C. difficile 11/11 
Reduced susceptibility to 
metronidazole 
Baines et al., 2008 
C. difficile SU1244 Resistant to fluoroquinolones 
Gift from Prof Andrej Weintraub, 
Karolinska University Hospital, 
Stockholm, Sweden 
B. fragilis GBR7 B. fragilis nimA gene present Löfmark et al., 2005 
B. fragilis 638R B. fragilis nimA-H gene absent Privitera et al., 1979 
B. fragilis 615nimJ 
B. fragilis nimJ present Husain et al., 2013 
B. fragilis 616nimJ 
 
4.2.2 Antimicrobial susceptibility testing 
Susceptibilities to clindamycin (CLI 10 µg), ciprofloxacin (CIP 5 µg), tetracycline (TET 30 
µg), cefotaxime (CTX 30 µg) and ceftriaxone (CRO 30 µg) were determined by the disc 
diffusion method according to the manufacturer’s instructions (Oxoid). Three biological 
repeats for each antimicrobial were performed. The minimum inhibitory concentrations 
(MICs) of metronidazole (MET), vancomycin (VA), erythromycin (ERY) and moxifloxacin 
(MOX) were determined by the Etest method according to the manufacturer’s instructions 
(bioMérieux) in single tests. For both methods, the initial bacterial inoculum was prepared in 
20 ml Wilkins Chalgren (WC) broth (Oxoid) and after an 18 hour incubation period the broth 
culture suspensions were normalised to 0.1 OD600 in WC medium. The disc diffusion method 
was performed on WC agar as previously described (Barbut et al., 1999). The diameter of the 
zones of inhibition surrounding the discs was measured with a ruler. In addition, the Etests 
were performed on Brucella agar supplemented with blood as previously described (Baines et 
al., 2008). The metronidazole Etest was also performed on WC agar. Agar plates were 
incubated anaerobically at 37ºC for 24 hours. The MIC breakpoints for the Etest method were 
defined as VA ≥ 32 µg/ml, MET ≥ 32 µg/ml, ERY ≥ 8 µg/ml and MOX ≥ 8 µg/ml according 
to the Clinical and Laboratory Standards Institute (CLSI, 2014). Clinical breakpoints for the 
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disc diffusion method have not been defined for C. difficile. The metronidazole MICs 
determined on the two types of media were analysed for statistical significance using a Mann-
Whitney test performed using SOFAstats (v. 1.4.3.). 
4.2.3 Genetic determination of antimicrobial resistance 
DNA template, obtained by cell lysis as described in Chapter 2 (section 2.2.4), was used for 
PCR screening of strains for nim and ermB genes. Purified genomic DNA, obtained as 
described in Chapter 3 (section 3.2.2) was used for PCR amplification of gyrA and gyrB. 
 
Table 4.2 Primers used for genetic-based analysis of antimicrobial resistance 
 











R: GCTTCCTTGCCTGTCATGTGCTC 458 






















390 Dridi et al., 2002 
*The nimJ F-primer was designed by Dr R Meggersee, a co-author of the published study (Husain et al., 2013). 
 
4.2.3.1 PCR screening for various nim genes 
PCR screening for the B. fragilis nimA-H genes, using the published “universal” nim primers 
(Table 4.2), was performed (Trinh & Reysset, 1996). B. fragilis 638R and B. fragilis GBR7 
strains were used as negative and positive controls, respectively. PCRs were performed in  
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25 µl reaction volumes containing KAPA ReadyMix (Kapa Biosystems) and 0.2 µM of each 
primer. PCR screening for a putative B. fragilis nimJ gene, using previously designed primers 
(Table 4.2), was performed. B. fragilis strains 615nimJ and 616nimJ strains were used as 
positive controls (Husain et al., 2013). A PCR using published primers designed to detect a 
putative C. difficile nim-like gene, as published in the genome sequence of C. difficile 630 
(CD630_14590), was performed. The C. difficile 11/11 control strain was included in the 
screening for the putative C. difficile nim-like gene. These PCRs were performed as 
mentioned above for the Bacteroides nimA-H genes, except that reactions contained 0.4 µM 
of each primer. All reaction mixtures were initially denatured at 95ºC for 5 min, and subjected 
to 30 cycles of 95ºC for 45 s, 53ºC for 45 s and 72ºC for 1 min, followed by 72ºC for 7 min. 
4.2.3.2 PCR screening for the C. difficile ermB gene 
PCR screening for the ermB gene, using published primers (Table 4.2), was performed 
(Johnson et al., 1999). PCRs were performed in 50 µl reaction volumes containing KAPA 
ReadyMix (Kapa Biosystems) and 0.7 µM of each primer. A single modification to the 
published thermal cycling conditions was made: 72ºC for 40 s instead of 3 min. 
4.2.3.3 PCR amplification and sequencing of the C. difficile gyrA and gyrB genes  
Published primers targeting the gyrA and gyrB genes (Table 4.2) were added to separate 25 µl 
reactions with 100 ng of template and 0.3 µM of each primer in Kapa HiFi HotStart 
ReadyMix (Kapa Biosystems). C. difficile SU1244 is resistant to fluoroquinolones and was 
used as a PCR positive control for both the gyrA and gyrB genes. PCRs previously described 
were modified (Dridi et al., 2002). The reactions were denatured at 95ºC for 5 min, and then 
subjected to 25 cycles of 98ºC for 20 s, 55ºC for 15 s and 72ºC for 30 s, followed by a final 
extension at 72ºC for 5 min. 
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PCR products of gyrA and gyrB were cloned into the pJet1.2 vector (Thermo Scientific) and 
sequenced using the pJet1.2-F/R primer pair as described in Chapter 3 (section 3.2.4). Nucleic 
acid sequences were analysed and amino acid sequences were derived using DNAMAN  
(v. 4.13). The published nucleic acid sequences for the gyrA and gyrB genes of the wild type  
C. difficile 630 strain were obtained from the NCBI database (CD630_00060 and 
CD630_00050, respectively), as well as three Groote Schuur Hospital isolates sensitive to 
moxifloxacin (GSH9316, GSH4696 and GSH5760) were included in the analysis as controls. 
Amino acid alignments for GyrA and GyrB were performed using MEGA (v. 5.05) (Tamura 
et al., 2011). Substitutions were searched for manually.  
 
4.3 Results and Discussion 
4.3.1 Antimicrobial susceptibility profiles 
The antimicrobial susceptibility profiles of the C. difficile clinical isolates were characterised 
by the Etest and disc diffusion methods. The distributions of minimum inhibitory 
concentrations (MICs) of vancomycin, metronidazole, erythromycin and moxifloxacin for  
C. difficile isolates belonging to different ribotypes are shown in Figure 4.1 and Table 4.3. In 
this study, none of the clinical isolates were resistant (≥ 32 µg/ml) to metronidazole or 
vancomycin (Figure 4.1 a, b and c); however, according to the epidemiological cut-off values 
(ECOFFs) published by the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST, v. 5.0, valid 2015.01.01), four or five isolates displayed reduced susceptibility to 
metronidazole (ECOFF ≥ 2 µg/ml), depending on the type of media used. Resistance to 
moxifloxacin and erythromycin (≥ 8 µg/ml) was found in 32% and 53% of the isolates 
(Figure 4.1 d and e), respectively, while four isolates (12%) displayed reduced susceptibility 




Figure 4.1 The distribution of MICs determined by Etests for clinical isolates belonging 
to different PCR ribotypes. (a) Metronidazole tested on Wilkins Chalgren (WC) agar, and 
(b) metronidazole, (c) vancomycin, (d) moxifloxacin and (e) erythromycin tested on Brucella 
blood (BB) agar. The key to PCR ribotype colours is shown in (e). The ECOFFs are 




















































































































































































































































































































































































































































































Table 4.3 Minimum inhibitory concentrations of antimicrobials and the presence of resistance 
genes or mutations in the GSH clinical isolates 








ermB gyrA/gyrB mutation 
(amino acid 
substitution) 
GSH0574 SE 9 0.064 0.5 0.38 0.75 N - 
GSH1588 001 0.19 0.5 0.5 0.5 N - 
GSH8033 056 0.19 0.38 0.75 0.5 N - 
GSH4115 001 0.125 0.25 0.75 0.5 N - 
GSH0541 SA 1 0.125 0.25 1 0.5 N - 
GSH5681 SE 21e 0.19 0.25 1 0.5 N - 
GSH2753 012 0.75 0.38 1 0.5 N - 
GSH1795 015 0.094 0.25 1 0.5 N - 
GSH9173 015 0.19 0.25 1 0.5 N - 
GSH8162 001 0.094 0.25 1 0.5 N - 
GSH5291 SE 23a 0.094 0.5 1 0.75 N - 
GSH1239 002 0.19 0.38 1.5 0.5 N - 
GSH4696 015 0.125 0.5 1.5 0.75 N none 
GSH9316 001 0.125 0.75 1.5 0.75 N none 
GSH9354 SE 108 0.125 0.25 2 0.5 N - 
GSH1858 SE 108 0.125 0.25 48 0.75 N - 
GSH2702 001 0.19 0.38 >256 0.5 Y - 
GSH6553 SE 19m 0.38 0.38 >256 0.75 Y - 
GSH5760 017 3 0.25 >256 0.75 Y none 
GSH5556 017 0.38 0.38 1 4 N gyrB (Asp426Asn) 
GSH4693 017 0.5 0.38 >256 6 Y gyrB (Asp426Asn) 
GSH5567 017 0.38 0.38 >256 6 Y gyrB (Asp426Asn) 
GSH1526 017 0.094 0.38 >256 6 Y gyrB (Asp426Asn) 
GSH2529 017 0.094 0.25 48 16 N gyrA (Thr82Ile) 
GSH4722 017 2 0.38 >256 16 Y gyrA (Thr82Ile) 
GSH1709 017 2 0.38 >256 16 Y gyrA (Thr82Ile) 
GSH2797 017 2 0.38 >256 16 Y gyrA (Thr82Ile) 
GSH6999 017 0.75 0.5 >256 16 Y gyrA (Thr82Ile) 
GSH3758 017 0.5 0.25 >256 >32 Y gyrA (Thr82Ile, Asp71Glu) 
GSH8043 017 0.38 0.25 >256 >32 Y gyrA (Thr82Ile, Asp71Glu) 
GSH8880 017 0.25 0.38 >256 >32 Y gyrA (Thr82Ile) 
GSH3235 017 1.5 0.38 >256 >32 Y gyrA (Thr82Ile) 
GSH1983 017 0.5 0.38 >256 >32 Y gyrA (Thr82Ile) 
GSH0616 017 0.38 0.38 >256 > 32 Y gyrA (Thr82Ile) 
Circled values indicate resistance and values shown in bold indicate reduced susceptibility. The MIC resistance breakpoints 
for antimicrobials according to the CLSI (2007) are as follows:  MET ≥ 32 µg/ml, VA ≥ 32 µg/ml, ERY ≥ 8 µg/ml and MOX 
≥ 8 µg/ml. The MIC breakpoints of reduced susceptibility for antimicrobials according to EUCAST (2015) are as follows: 
MET ≥ 2 µg/ml, VA ≥ 2 µg/ml and MOX ≥ 4 µg/ml. The MIC breakpoint of reduced susceptibility for ERY is not available. 
Y and N indicate the presence and absence of the ermB gene, respectively. ‘None’ indicates the absence of mutations in the 
gyrA and gyrB genes. All the ribotype 017 strains had the Ser366Ala substitution in GyrB. A dash (-) indicates that 
the respective experiment was not conducted as it was not applicable. 
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Table 4.4 Minimum inhibitory concentrations of antimicrobials and the presence of resistance 










(µg/ml) ermB gyrA/gyrB mutation 
M120  078 0.125 0.38 0.75 0.5 N - 
CD305 023 0.19 0.38 1 0.5 N - 
CD196 027 0.25 0.38 1 0.5 N - 
CF5 017 0.25 0.38 1 0.75 N - 
630 012 0.094 0.25 >256 0.5 Y none 
M68 017 1 0.38 >256 6 Y gyrB (Asp426Val) 
R20291 027 1 0.25 >256 12 Y gyrA (Thr82Ile) 
11/11 001 6 - 8 0.38  >256 > 32 - - 
700057 038 <0.016 0.5 2 <0.002 - - 
Circled values indicate resistance and values shown in bold indicate reduced susceptibility. The MIC resistance breakpoints 
for antimicrobials according to the CLSI (2007) are as follows:  MET ≥ 32 µg/ml, VA ≥ 32 µg/ml, ERY ≥ 8 µg/ml and MOX 
≥ 8 µg/ml. The MIC breakpoints of reduced susceptibility for antimicrobials according to EUCAST (2015) are as follows: 
MET ≥ 2 µg/ml, VA ≥ 2 µg/ml and MOX ≥ 4 µg/ml. The MIC breakpoint of reduced susceptibility for ERY is not available. 
Y and N indicate the presence and absence of the ermB gene, respectively. ‘None’ indicates the absence of mutations in the 
gyrA and gyrB genes. All the ribotype 017 strains had the Ser366Ala substitution in GyrB. A dash (-) indicates that 
the respective experiment was not conducted as it was not applicable. C. difficile 11/11 was used as a reference strain for 
metronidazole resistance and, therefore, the ermB gene and mutations in the gyrA or gyrB genes were not screened for.  
 
Metronidazole 
The MIC distribution of metronidazole tested on Wilkins Chalgren (WC) ranged from 0.094 – 
2 µg/ml (Figure 4.1 a), whereas MICs tested on Brucella blood (BB) agar ranged from 0.094 
– 6 µg/ml (Figure 4.1 b). The distribution of MICs for the various ribotypes differed between 
the two media. However, the difference in MICs between them was not statistically 
significant (p = 0.762). Published studies have reported that the composition of the agar can 
affect the magnitude of the MIC (Baines et al., 2008). While all the isolates in this study were 
sensitive to metronidazole (≤ 32 µg/ml), five isolates (15% of the study group) displayed 
reduced susceptibility (ECOFF ≤ 2 µg/ml) when tested on WC agar (Figure 4.1 a), and four 
isolates (12%) displayed reduced susceptibility when tested on BB agar (Figure 4.1 b). The  
C. difficile 11/11 control strain (ribotype 001), known to display reduced susceptibility had an 
MIC of 6 – 8 µg/ml (Table 4.4). Published studies have reported reduced susceptibility to 
metronidazole in C. difficile belonging to ribotypes 001 and 010 (Baines et al., 2008; Moura 
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et al., 2013; Peláez et al., 2008). In this study, all isolates belonging to ribotype 001 were 
sensitive to metronidazole (0.064 – 0.19 µg/ml) (Figure 4.1). Ribotype 027 has also been 
reported to display reduced metronidazole susceptibility (Martin et al., 2008); however, the 
ribotype 027 reference strains in this study were sensitive. Interestingly, all the isolates 
displaying reduced susceptibility on both media belonged to ribotype 017. Reduced 
susceptibility of ribotype 017 strains to metronidazole has not been previously reported. The 
MICs of these 4 – 5 isolates are clinically relevant as they are near the upper limit of the 
metronidazole concentration that can be achieved in the intestine during therapy 
(approximately 9.5 µg/g faeces) (Bolton & Culshaw, 1986).  
Vancomycin 
MICs of vancomycin were distributed over a narrow range (0.25 – 0.75 µg/ml) as shown in 
Figure 4.1 (c) and all the clinical isolates were sensitive to vancomycin (ECOFF ≤ 2 µg/ml). 
This sensitivity to vancomycin has also been reported by European-wide studies (Barbut et 
al., 2007; Freeman et al., 2015). A few studies have reported reduced susceptibility or 
resistance (≥ 32 µg/ml) to vancomycin. However, different antimicrobial testing methods 
were used and it is, therefore, not possible to compare those MICs to the current study (Chia 
et al., 2013; Ngamskulrungroj et al., 2015). Unlike the case for metronidazole, it is possible to 
achieve vancomycin concentrations as high as 1000 – 5000 µg/ml in the intestine (Edlund et 
al., 1997). The low MICs of vancomycin reported by this study suggest that vancomycin 
remains an effective antimicrobial for treating CDI within this setting.  
Moxifloxacin 
Only ribotype 017 isolates displayed resistance or reduced susceptibility to moxifloxacin. The 
occurrence of resistance to moxifloxacin (≥ 8 µg/ml) was 32% (Figure 4.1 d) and four isolates 
(12%) displayed reduced susceptibility (ECOFF ≥ 4 µg/ml), as well as the C. difficile M68 
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and R20291 reference strains (Table 4.4). Some published studies report that resistance to 
moxifloxacin has been associated significantly with previous use of fluoroquinolones while 
other studies disagree (Ackermann et al., 2003; Barbut et al., 2007). It was not possible to 
gather data regarding previous antimicrobial use for patients enrolled in the current study. 
Such data is important in future work to determine whether fluoroquinolone use is a risk 
factor for developing CDI at Groote Schuur Hospital. In this study, only one ribotype 017 
isolate, GSH5760, was sensitive to moxifloxacin (Table 4.3). Within the MLVA minimum 
spanning tree (Chapter 3), three isolates (GSH4693, GSH5567 and GSH1526) out of the four 
that displayed reduced susceptibility to moxifloxacin were clustered together. A further 
common phenotype amongst these three was their resistance to erythromycin (≥ 256 µg/ml) 
while the fourth isolate (GSH5556) showing reduced susceptibility to moxifloxacin clustered 
separately and was sensitive to erythromycin (1 µg/ml) (Table 4.3).  
Erythromycin 
The occurrence of resistance to erythromycin (≥ 8 µg/ml) was 53%. The MICs for two 
isolates were 48 µg/ml and it was ≥ 256 µg/ml for the remaining resistant isolates. These 
latter values were regarded as highly resistant (Table 4.3). An ECOFF value for erythromycin 
has not been published for C. difficile by EUCAST, and so isolates displaying reduced 
susceptibility could not be determined. The highly resistant isolates were ribotype 017 strains 
with the exception of isolates GSH6553 and GSH2702, which were ribotypes SE19m and 
001, respectively (Table 4.3). In the MLVA minimum spanning tree (Chapter 3), the ribotype 
SE19m isolate has the least genetic distance from ribotype 027 reference strain R20291, 
which also displayed high-level resistance to erythromycin (Table 4.4).  
Eleven isolates (32%) displayed co-resistance to erythromycin and moxifloxacin and their 
MICs are circled in Table 4.3. These isolates were all ribotype 017. Moxifloxacin resistance 
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has been commonly found to be together with erythromycin and/or clindamycin resistance in 
C. difficile (Ackermann et al., 2003; Lachowicz et al., 2014), although there seems to be no 
genetic link between the two resistance mechanisms. Published studies have also described 
ribotype 017 as a multi-drug resistant pathogen (Drudy et al., 2007a; Kim et al., 2012b; 
Pituch et al., 2011). Although the ribotype 017 isolates appeared to be more resistant than the 
non-017 isolates, statistical analysis to determine whether this was significant could not be 
done as the study group was not large enough. 
Disc diffusion 
The susceptibility to clindamycin, ciprofloxacin, ceftriaxone, cefotaxime and tetracycline was 
determined by the disc diffusion method due to the high costs of Etest strips. The distribution 
of antimicrobial susceptibilities, defined by the diameter of the zone of inhibition, for Groote 
Schuur Hospital clinical isolates is summarised in Figure 4.2. Clinical breakpoints for the disc 
diffusion method have not been defined for C. difficile. Therefore, the proportion of clinically 
resistant isolates to these antimicrobials could not be determined. However, 50%, 44% and 
71% of the GSH isolates gave no zone of inhibition around the discs containing clindamycin, 
ciprofloxacin and cefotaxime, respectively (Figure 4.2 a, b and d), suggesting resistance to 
these antimicrobials. Overall, clinical isolates showed no zones or smaller zones of inhibition 
to cefotaxime than to ceftriaxone, both of which are third-generation cephalosporins (Figure 
4.2 c and d). One isolate, ribotype 012, formed a zone much smaller than the rest of the study 
group to tetracycline (Figure 4.2 e). A diameter of 14 mm may be indicative of resistance. A 
previous European study reported tetracycline resistance primarily in ribotype 012 and 048 
strains (Spigaglia et al., 2011). Overall, in this study, isolates forming smaller zones of 




Figure 4.2 The distribution of antimicrobial susceptibilities determined by disc diffusion. 
(a) Clindamycin, (b) ciprofloxacin, (c) ceftriaxone, (d) cefotaxime and (e) tetracycline tested 
on Wilkins Chalgren (WC) agar. The key to PCR ribotype colours is shown in (e). The graphs 
are oriented according to increasing antimicrobial resistance, with smaller zones of inhibition 
plotted on the right. A diameter of 7 mm represents the diameter of the disc (i.e. no zone of 
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The Etest method is an effective method of determining the MIC for particular antimicrobials, 
however it is expensive and, therefore, not all antimicrobials could be tested by this method. 
The disc diffusion method is much cheaper, and was used for older generation antimicrobials, 
none of which are used to treat CDI. A published study correlated the diameters produced by 
disc diffusion to MICs produced by Etests and demonstrated disc diffusion as a reliable 
method for distinguishing susceptible and resistant C. difficile strains (Erikstrup et al., 2012). 
The data presented here cannot be compared to the published study as only vancomycin, 
metronidazole and moxifloxacin were investigated. The clinical breakpoint values specific for 
C. difficile have yet to be established. However, the data reported serves as an indication of 
potential resistance displayed by various isolates, especially those belonging to ribotype 017. 
Future work on potentially resistant strains could include Etests to confirm true resistance.  
 
4.3.2 Genetic determinants of antimicrobial resistance 
To investigate the possible genetic mechanism of the reduced susceptibility to metronidazole 
observed in C. difficile, PCRs were performed to screen for the various published nim genes, 
which often play a role in metronidazole resistance in B. fragilis. The B. fragilis “universal” 
nim primers that target conserved sequences in the Bacteroides nimA-H genes and the specific 
B. fragilis nimJ primers, successfully amplified targets in the respective  
B. fragilis positive control strains. However, none of the C. difficile clinical isolates were 
shown to harbour homologues of these genes (4.3 a and b). An additional putative 
chromosomal nim gene, which had been annotated in the C. difficile genome sequence, was 
screened for by PCR using gene-specific primers. This C. difficile nim-like gene was found in 
all the C. difficile clinical isolates regardless of their metronidazole sensitivity or reduced 















Figure 4.3 Representative gel images showing PCR screening for the various nim genes 
and the C. difficile ermB gene: (a) The B. fragilis nimA gene present in the B fragilis GBR7 
control strain, (b) the B. fragilis nimJ gene present in the B. fragilis 615nimJ and 616nimJ 
control strains, (c) the putative C. difficile nim-like gene present in the C. difficile 11/11 
control strain and all the GSH clinical isolates, and (d) the C. difficile ermB gene present in 
the erythromycin resistant C. difficile isolates. S = sensitive, I = reduced susceptibility and  
R = resistant. M, 100 bp DNA Molecular weight ladder.  
  
M 
B. fragilis nimA-H (458 bp) 
500 bp  
400 bp  
900 bp  
800 bp  
500 bp  
400 bp  
300 bp  
M 
800 bp  
700 bp  
600 bp  
B. fragilis nimJ (498 bp) 
C. difficile nim (863 bp) 
C. difficile ermB (688 bp) 




B. fragilis C. difficile 





























The primers targeting the B. fragilis nimA-H genes have successfully amplified homologous 
nim genes in several species including one strain of Clostridium bifermentans (Lubbe et al., 
1999); however, it has not been possible to detect nim genes in C. difficile using these primers 
(Brazier et al., 2001; Peláez et al., 2008). Annotated genome sequences for C. difficile have 
revealed several putative nim-like genes amongst different strains, although functional 
characterisation of these genes is lacking. The C. difficile gene-specific primers, designed to 
detect a chromosomally annotated putative nim-like gene, recognised it in all the clinical 
isolates, irrespective of whether they were sensitive or resistant to metronidazole. Its presence 
in the isolates sensitive to metronidazole suggests that it is not involved in the observed 
phenotype of reduced susceptibility to metronidazole. 
The underlying genetic mechanism for the reduced susceptibility to metronidazole observed 
in some of the C. difficile clinical isolates has, therefore, yet to be determined. A recent study, 
using whole genome sequencing, reported SNPs in several genes involved in essential 
metabolic pathways of a stably metronidazole resistant strain that may confer resistance 
(Lynch et al., 2013). A recent proteomic study reported the increased expression of several 
proteins, such as putative 5-nitroimidazole reductases, and proteins involved in DNA repair, 
in a stably metronidazole resistant C. difficile strain (Chong et al., 2014). This was observed 
even in the presence of metronidazole, which reduced the cell density and sporulation of the 
resistant strain. These putative 5-nitroimidazole reductases are expressed by genes other than 
the nimA-H or nimJ genes that were screened for in this current study, and could be targets in 
future studies. The identification of these proteins suggests that several factors and pathways 
may be associated with metronidazole resistance in C. difficile and this warrants further 
investigation. 
Primers targeting the C. difficile ermB gene were used to investigate the underlying genetic 
basis for erythromycin resistance. The ermB gene was found in C. difficile isolates displaying 
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high-level resistance (HR) to erythromycin (≥ 256 µg/ml), which represents 47% of the 
clinical isolates (Figure 4.3 d and Table 4.5). C. difficile reference strains 630, M68 and 
R20291 also displayed high-level resistance to erythromycin and harboured the ermB gene 
(Table 4.4). These results suggest that the ermB gene is a common determinant for high-level 
resistance to erythromycin among the Groote Schuur Hospital clinical isolates. Resistant 
isolates with an MIC of 48 µg/ml did not harbour the ermB gene. The mechanism by which 
these isolates display some level of resistance has yet to be determined. Alternative 
erythromycin resistance mechanisms could include other erm genes, efflux pumps or a 
mutation in the target sequence in the 23S rRNA (Ambrose et al., 2005; Eady et al., 1993; 
Wittmann et al., 1973). Future investigations of efflux pump activity could include examining 
the effect of efflux pump inhibitors, such as carbonyl cyanide 3-chlorophenylhydrazone 
(CCCP), reserpine or sodium orthovanadate, on antimicrobial susceptibility (Drudy et al., 
2006; Spigaglia et al., 2011). 
 
Table 4.5 A summary of erythromycin susceptibility and the presence of the ermB gene 
among the clinical isolates  
Susceptibility Etest MIC (µg/ml) Prevalence ermB gene 
S 0.38 - 1.5 47% N 
R 48 6% N 
HR ≥ 256 47% Y 
S = sensitive, R = resistant and HR = high level resistance. Y and N indicate the presence and absence of the ermB gene. 
 
The gyrA and gyrB genes of all the ribotype 017 isolates were sequenced as only strains of 
this ribotype displayed some level of resistance to moxifloxacin. The results are shown in 
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Table 4.3 and summarised in Table 4.6. All clinical isolates with a moxifloxacin MIC of 16 or 
≥ 32 µg/ml had a mutation in the gyrA gene resulting in an amino acid substation of 
Thr82Ile. Isolates GSH3758 and GSH8043 had an additional mutation in gyrA leading to 
an Asp71Glu substitution. All the clinical isolates with an MIC of 4 or 6 µg/ml had a 
mutation in the gyrB gene leading to an Asp426Asn amino acid substitution, while the  
C. difficile M68 reference strain (ribotype 017) with an MIC of 6 µg/ml had an Asp426Val 
substitution in GyrB (Table 4.4). All the ribotype 017 strains, including the C. difficile M68 
reference strain and the single sensitive ribotype 017 isolate (GSH5760), had the Ser366Ala 
substitution in GyrB.  
 
Table 4.6 A summary of moxifloxacin susceptibility and the presence of resistance-causing 











3% none none 








*S = sensitive, I = reduced susceptibility, R = resistant and HR = high level resistance. 
†Asp71Glu was observed in only two isolates, GSH3758 and GSH8043, as shown in Table 4.3. 
‡All the ribotype 017 isolates had the Ser366Ala substitution in GyrB. 
 
None of the mutations found in the clinical isolates were novel. The Thr82Ile and 
Asp71Glu substitutions in GyrA, and the Asp426Asn substitution in GyrB have been 
previously published and associated with fluoroquinolone resistance (Dridi et al., 2002; 
Drudy et al., 2006). The Asp426Val substitution in GyrB of the C.difficile M68 has also 
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been previously published, and was found in all the ribotype 017 strains displaying high-level 
resistance to fluoroquinolone (Drudy et al., 2006). The Ser366Ala substitution in GyrB has 
been previously published; however, it does not play a role in fluoroquinolone resistance 
(Drudy et al., 2006). This is in agreement with the presence of the Ser366Ala in a 
moxifloxacin sensitive ribotype 017 isolate. Two sensitive non-ribotype 017 isolates, 
GSH4696 and GSH9316, were also selected for sequencing. Like the sequences of the wild 
type C. difficile 630 strain obtained from NCBI, they did not harbour any substitutions in 
GyrA or GyrB (Tables 4.3 and 4.4). 
The minimum spanning tree (Chapter 3) depicts GSH6999, GSH3758 and GSH8043 as 
isolates of the same MLVA type; however, isolate GSH6999 does not have the Asp71Glu 
amino acid substitution in GyrA. As discussed in Chapter 3, using extended MLVA 
(eMLVA) may be able to differentiate isolate GSH6999 as a separate MLVA type from the 
other two. In this study, the gyrA mutation resulting in a single amino acid substitution of 
Thr82Ile was associated with high-level resistance to moxifloxacin, whereas the gyrB 
mutation resulting in Asp426Asn was associated with intermediate-level resistance. 
 
4.4 Conclusion 
Antimicrobial susceptibility testing revealed resistance among the clinical isolates. All the 
clinical isolates were sensitive to vancomycin, while a few ribotype 017 isolates displayed 
reduced susceptibility to metronidazole, although this did not reach the levels of clinical 
significance. Erythromycin resistance was associated with ermB-positive isolates, while 
moxifloxacin resistance was associated with a Thr82Ile amino acid substitution in GyrA. 
These resistant characteristics were observed in 47% and 32% of the clinical isolates, 
respectively; and co-resistance was observed in 32% of the clinical isolates. 
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Antimicrobial pressure may explain the high prevalence of the 017 ribotype among the 
clinical isolates. The high prevalence of fluoroquinolone resistant ribotype 017 isolates may 
be a reflection of the high use of moxifloxacin to treat respiratory tract infections in Groote 
Schuur Hospital. In Korea, the increase in ribotype 017 strains occurred as moxifloxacin use 
was introduced (Lee et al., 2014). The majority of the ribotype 017 strains were resistant to 
moxifloxacin, as well as clindamycin, erythromycin and ciprofloxacin. While the data 
regarding specific antimicrobial treatment of the patients enrolled in this study were not 
available, the data reported by this study are of value to the hospital in the overall future 
monitoring of antimicrobial resistance among the patients and can be used to inform 
antimicrobial prescribing policies. Restriction of high-risk antimicrobials can be used as a 
strategy to reduce CDI.  
Antimicrobial characterisation revealed that ribotype 017 isolates were primarily high-level 
and multi-drug resistant. This resistance profile may provide them with an advantage over 
non-017 isolates to persist in the host intestine and lead to infection. Colonisation is another 
important step in the development of CDI. In order to determine whether ribotype 017 isolates 
have an advantage over the non-017 isolates, aspects of colonisation potential were 
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Colonisation of the host intestine by C. difficile together with the production of toxins are 
important steps in the development of infection. Sporulation then allows CDI patients to shed 
spores, which aid in the transmission of C. difficile. Several factors are thought to play a role 
in colonisation. These include the presence of adhesins, such as the phase-variable CwpV 
protein. Adhesins are expressed on the bacterial cell surface and may induce cellular 
aggregation of C. difficile and subsequently contribute towards colonisation. In the study 
reported here, attempts were made to determine the sporulation frequency and toxin 
production levels of the isolated strains. However, it was not possible to evaluate them or their 
possible relationship to colonisation due to the high physiological variation between replicate 
experiments. However, an auto-aggregation assay revealed that the ribotype 017 strains were 
significantly better auto-aggregators when compared to the other ribotypes investigated. A 
PCR targeting an inversion region upstream of the cwpV gene revealed that all the clinical 
isolates contained individuals within the population carrying the region in either orientation 
regardless of the differing auto-aggregating capacities of the population as a whole. Semi-
quantitative RT-PCR was performed to determine the transcription level of cwpV in three 
isolates of different auto-aggregation phenotypes. These showed differences in the 
transcription level between the isolates, suggesting that the expression level of CwpV may 




The development of disease caused by C. difficile is influenced by several factors. The ability 
to efficiently colonise the human host intestine and produce biologically active toxins during 
infection, and the capacity to produce spores have all been proposed to play a role in the 
acquisition and development of CDI. While the predominance of PCR ribotype 017 strains in 
this current study may be related to their resistance to multiple antimicrobials, additional 
factors such as their toxin levels, sporulation capacity, and ability to auto-aggregate and form 
biofilms may also play a role in their increased prevalence. These aspects were investigated in 
this study.    
The disease caused by C. difficile is mainly mediated by toxins A and B. There is variation in 
the amount of toxin produced by different strains. For example, isolates belonging to the 
ribotype 027 clade have been associated with increased and/or prolonged toxin production, 
thereby causing more severe disease (Akerlund et al., 2008; Vohra & Poxton, 2011; Warny et 
al., 2005). Conversely, A-B+ strains only produce functional toxin B, but are still able to cause 
severe disease (Drudy et al., 2007b; Kim et al., 2008; Kuijper et al., 2001). As discussed in 
Chapter 2, all but two of the C. difficile isolates investigated in this study harboured the toxin 
genes; however, the poor clinical sensitivities of the EI-based tests did not successfully 
establish the presence of toxins in many of the stool specimens. In order to determine whether 
the C. difficile isolated from the stool specimens have the potential to cause the disease 
experienced by the symptomatic patients, it is important to determine whether the various C. 
difficile strains have the ability to produce biologically active toxins. Toxins can be detected 
and quantitated using a cell culture neutralisation assay (CCNA) or an enzyme-linked 
immunosorbent assay (ELISA) (Hernández-Rocha et al., 2013; Lyerly et al., 1983; Nguyen et 
al., 1990). Alternatively, Darkoh et al. (2011b) developed a quantitative assay that detects 
toxin A and B activity. The assay involves using a chromogenic substrate, p-nitrophenyl-ß-D-
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glucopyranoside (PNPG), which is stereochemically similar to UDP-glucose, the substrate 
naturally targeted by toxins A and B. Cleavage of PNPG can be measured 
spectrophotometrically. This assay does not require specialised facilities and is cost effective. 
The ability of the bacteria to form spores plays an important role in CDI, since these structures 
are highly resistant to many environmental and antimicrobial factors enabling them to persist 
in the environment aiding in disease transmission (Fawley et al., 2007; Goldenberg et al., 
2012; Sjöberg et al., 2014). An increased sporulation frequency of some strain types, such as 
ribotype 027 strains, has been proposed to aid in their survival and spread (Akerlund et al., 
2008; Fawley et al., 2007). However, other studies have also reported that sporulation 
frequency is not associated with the strain type (Burns et al., 2010, 2011).  
Colonisation of the intestine requires the bacterium to interact with, and adhere to, the host 
tissue. This is mediated by cell surface-associated adhesion proteins. Amongst these, cell wall 
protein V (CwpV) has been reported to potentially play a role in colonisation by promoting 
auto-aggregation of C. difficile (Emerson et al., 2009; Reynolds et al., 2011). CwpV has a 
conserved N-terminal domain involved in cell wall anchoring and a variable C-terminal 
domain which mediates aggregation. The protein is encoded by the cwpV gene and expressed 
in a phase-variable manner, which is mediated by inversion of an upstream DNA region. One 
orientation allows the expression of cwpV (ON), while in the other orientation the gene is not 
transcribed (OFF). 
To further characterise the local clinical C. difficile isolates, their abilities to produce toxins, 
their sporulation frequency, and their auto-aggregation capacity were investigated and reported 
in this chapter.  
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5.2 Materials and Methods 
5.2.1 Bacterial strains  
The Groote Schuur Hospital C. difficile isolates listed in Table 2.5 (Chapter 2) and the  
C. difficile reference strains listed in Table 3.1 (Chapter 3) were included in the various 
analyses.  
5.2.2 Quantitative toxin activity assay 
Toxin A and B activities were detected by the Cdifftox activity assay for clinical C. difficile 
isolates using 30 mM PNPG, as previously described (Darkoh et al., 2011b). Cleavage of the 
PNPG substrate was measured spectrophotometrically at an absorbance of 405 nm since the 
filter for the published wavelength of 410 nm was not available to this study. The C. difficile 
R20291 and CD196 reference strains were included in the analysis as positive controls for the 
production of both toxins A and B. 
5.2.3 Sporulation frequency assay 
Sporulation frequency was measured using a published method (Burns et al., 2011). Starter 
cultures were prepared by growing cells for 18 hour in 20 ml BHI broth.  Fresh broth (20 ml) 
was inoculated with 200 µl starter culture and cultures were incubated until the OD600 was 
between 0.4 and 0.6 to allow any spores to germinate. Finally, this was used to inoculate fresh 
broth for the sporulation assay (time = 0) and incubated at 37ºC up to 120 hours. Total viable 
counts, as well as spore formation, were enumerated at 0 hour, 24 hours, 48 hours and  
120 hours incubation of culture. At each time point, a volume of 500 µl culture was subjected 
to heat shock at 65ºC for 25 min, and then serially diluted in PBS. At each time point, another 
volume of 500 µl culture was serially diluted in PBS (without heat-shock), for the total viable 
count. A volume of 100 µl was spread plated onto BHI agar supplemented with the bile salt 
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taurocholate (0.1% w/v, Sigma). The R20291 reference strain was used as a control as its 
sporulation frequency has been published (Burns et al., 2011). 
5.2.4 Auto-aggregation assay 
A previously published assay method was used (Purcell et al., 2012). The C. difficile clinical 
isolates and reference strains were grown in 15 ml BHI broth in test tubes at 37ºC for  
18 hours. Without mixing the cultures, the optical density at 600 nm was measured at 1 cm 
below the surface of the broth culture. The cultures were then vortexed until the aggregates 
were fully dispersed, and the optical densities were measured again. The auto-aggregation 
percentage was calculated as [(ODpost-vortex – ODpre-vortex) / ODpost-vortex] × 100. Five 
biological repeats were performed. The auto-aggregating capacities between the ribotype 017 
and the non-017 strains were analysed for statistical significance using a Mann-Whitney test 
performed using SOFAstats (v. 1.4.3.). 
5.2.5 Orientation-specific PCR targeting the inversion region upstream of the cwpV 
gene 
The orientation of the inverted region upstream of the cwpV gene was determined by PCR 
analysis. Two separate reactions amplifying the ON and OFF orientations were performed 
using published primers (Table 5.1) (Emerson et al., 2009). A total of 100 ng gDNA and  
0.2 µM of each primer were used in each 50 µl reaction using KAPA ReadyMix (Kapa 
Biosystems). Reactions were denatured at 95ºC for 5 min, and then subjected to 35 cycles of 
95ºC for 30 s, 45ºC for 30 s and 72ºC for 30 s, followed by a final extension at 72ºC for  
7 min. All the C. difficile clinical isolates and reference strains were included in the analyses. 
PCR products of the ON and OFF orientation of the C. difficile 630 reference strain were 
cloned into the pJet1.2 vector (Thermo Scientific) and sequenced using the pJet1.2-F/R primer 
pair as described in Chapter 3 (section 3.2.4). The nucleic acid sequence of the inversion 
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region of the published C. difficile 630 strain as well as R20291, CD196, M68 and CF5 were 
obtained from the NCBI database and were included for nucleic acid sequence alignment 
using MEGA (v. 5.05) (Tamura et al., 2011). 
 
Table 5.1 Primers used to investigate the cwpV gene 
Gene 



















R1391: GACGGGCGGTGTGTACAA 502 
Metcalf et 
al., 2010 




5.2.6 RNA extraction and reverse transcription PCR of the cwpV gene 
The expression of the cwpV gene in C. difficile was investigated by reverse-transcription PCR 
(RT-PCR). The 16S rRNA gene was used as a reference gene to normalise the expression 
level of cwpV (Metcalf et al., 2010). Three biological replicates were analysed. 
Total RNA was extracted from C. difficile strains using a modified hot phenol method 
(Rafudeen, 2001). Briefly, C. difficile was cultured in 10 ml BHI broth until the OD600 was 
between 0.4 and 0.6 and harvested by centrifugation (2500 x g for 10 min). Cell pellets were 
resuspended in 500 µl resuspension buffer (0.3 M sucrose, 0.01 M sodium acetate, pH 4). To 
lyse the cells, 500 µl of lysis buffer (2% SDS, 0.01 M sodium acetate, pH 4) was added and 
the mixture was incubated at 65ºC for 1.5 min. A volume of 1 ml water-saturated phenol  
100 
 
(pH 4) was added. The samples were mixed, incubated further at 65ºC for  
3 min and then cooled at -80ºC for 1 min. The aqueous phase was recovered by centrifugation 
(8000 x g for 5 min). Hot phenol extractions were repeated until the aqueous phase was clear. 
RNA was precipitated by the addition of 1/6.6 vol of 3 M sodium acetate (pH 5.5) and 3 vol 
absolute ethanol, and left at -80ºC for 30 min. After centrifugation (10 000 rpm for 10 min) the 
pellet was resuspended in 200 µl 1X DNase I Buffer (Thermo Scientific). DNase I (Thermo 
Scientific) was added (10 U), and the samples were left at 37ºC for 3 hours. Finally, DNase-
treated RNA was purified using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions.  
RNA was reverse transcribed into cDNA using the Tetro cDNA Synthesis Kit (Bioline) 
according to the manufacturer’s instructions, using 5 µg total RNA and random hexamers. A  
5 µl volume of cDNA was used to amplify the cwpV and 16S rRNA genes in a multiplex PCR 
using published primers (Table 5.1) (Emerson et al., 2009; Metcalf et al., 2010). PCRs were 
performed in 50 µl reaction volumes containing KAPA ReadyMix (Kapa Biosystems) and  
0.2 µM of each cwpV and 16S rRNA primers. The reactions were denatured at 95ºC for  
5 min, and then subjected to 30 cycles of 95ºC for 30 s, 45ºC for 30 s and 72ºC for 40 s, 
followed by a final extension at 72ºC for 7 min.  Genomic DNA from the M68 reference strain 
was used as a PCR control.  
The expression level of cwpV was semi-quantified by determining the band intensity of the 





5.3 Results and Discussion 
5.3.1 Toxin activity of the clinical isolates 
The quantitative toxin assay of Darkoh et al., (2011b) was attempted in order to determine 
whether the clinical isolates produce biologically active toxins and whether some strains 
produce more toxins than others. Four C. difficile strains were selected to test the toxin assay: 
a non-toxigenic strain (GSH0541), a ribotype 017 strain (GSH6999), and the CD196 and 
R20291 positive control reference strains. However, toxin production of the clinical isolates 
could not be quantitated as the toxin activity could not be detected, even in the published 
R20291 ribotype 027 reference strain, which is known to have increased toxin production 
(Akerlund et al., 2008; Vohra & Poxton, 2011; Warny et al., 2005). The assay involved 
cleavage of a substrate by the toxins in the culture supernatant resulting in a colour change, 
which was quantified using a spectrophotometer. The OD405 of the clinical isolates did not 
differ from the negative control, containing no culture supernatant. Using a wavelength of 405 
nm instead of 410 nm did not pose a problem as a Nanodrop analysis showed no significant 
difference in the absorbance of p-nitrophenol between these two wavelengths. This toxin assay 
was used as it did not require the specialised facilities that are required for other types of assay 
and were not available to this study. It is unclear why the assay was not successful and after 
several attempts the assay was discontinued. An alternative more sensitive toxin assay method 
is currently being performed by a USA-based collaborator (Merrigan et al., 2013).   
 
5.3.2 Sporulation frequency of the clinical isolates 
The sporulation assay was performed in order to determine whether some isolates had a higher 
sporulation frequency, and whether there was an association between sporulation frequency 
and ribotype. The more frequent production of spores by certain ribotype groups may lead to a 
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larger reservoir of spores belonging to those strains in the hospital environment, allowing them 
to spread more easily, which may help to explain the increased prevalence of various 
ribotypes. The following strains were used to test the sporulation assay: a non-toxigenic strain 
(GSH0574), two ribotype 017 strains (GSH6999 and GSH3758), a ribotype 002 strain 
(GSH1239), and the R20291 ribotype 027 reference strain as a positive control. Sporulation 
was measured based on colony forming units (CFU) derived from spores after heat shock. 
However, an accurate sporulation frequency for the clinical isolates could not be determined 
as the assay posed certain complications. Firstly, the number of heat-resistant CFU at time = 0 
could not be normalised as was required by the method (Burns et al., 2011). In order to 
accurately follow the production of spores, it is essential to begin the assay with zero spores at 
the time of inoculation (time = 0). In an attempt to do this, starter broth cultures were prepared 
by inoculating 18 hour broth cultures into fresh broth and incubating until the OD600 was 
between 0.4 and 0.6 to allow any residual spores to germinate. These were then inoculated into 
fresh broth for the sporulation assay. However, aliquots removed at this time point still 
showed evidence of heat-resistant spores. This may be the result of slow germinating spores 
from the starter culture that only began to germinate once plated onto the taurocholate-
containing agar medium. Secondly, the sporulation frequency varied greatly between 
biological repeats. The bacterial growth rate or the rate of sporulation of the various strains 
may be sensitive to unknown factors in the growth conditions and media. Additionally, spore 
resistance and germination ability may vary even within strain types, and all these factors may 
explain the variation across the repeated experiments. The assay was discontinued after several 
biological and technical repeat experiments failed to give reproducible results.  
Published studies have reported conflicting data as to whether there is a direct correlation 
between sporulation and ribotype, with some reporting that the sporulation frequency can vary 
among isolates belonging to the same ribotype (Burns et al., 2010, 2011; Lynch et al., 2013). 
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Even studies that included the same C. difficile strains for analyses have reported differing 
results, suggesting that there is too much variation using the current methods. An alternative 
method to measure sporulation involves the use of phase-contrast microscopy (Burns et al., 
2011). This method is simpler as it does not require treatment of bacterial broth culture and it 
is easy to distinguish spores from vegetative cells (the difference can be further enhanced by 
staining) (Fawley et al., 2007; Underwood et al., 2009). Unfortunately, there is no “preferred” 
method for determining sporulation frequency and the development of an improved method is 
necessary to determine the sporulation of C. difficile more accurately.  
 
5.3.3 Auto-aggregation  
When the C. difficile isolates were cultured in broth throughout the study, the ribotype 017 
strains showed a strong tendency to auto-aggregate and settle at the bottom of the growth 
container. The settled cells formed a tight clump that required vigorous vortexing for cell 
dispersal. An assay was performed to determine whether the C. difficile strains were able to 
aggregate to one another within a population, and whether there was an association between 
the auto-aggregating capacity and ribotype. A greater auto-aggregating capacity by certain 
ribotypes may enhance their ability to colonise the host intestine, thereby out-competing other 
ribotypes during the colonisation process. Various auto-aggregating phenotypes in bacterial 
broth culture were observed among the C. difficile clinical isolates and reference strains 
(Figure 5.1). The auto-aggregation percentage of the various strains was calculated and is an 
indication of the proportion of the bacterial population within the broth culture that was 









Figure 5.1 Auto-aggregation of C. difficile bacterial cells. (a) A representation of the 
various auto-aggregating phenotypes observed in BHI broth culture. The turbidity of the broth 
culture is evenly distributed and no clumping is observed in ribotype 027 and 001. Partial and 
complete clumping is observed in the ribotype 017 strains. (b) A representation of broth 
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Figure 5.2 Auto-aggregation percentages. The distribution of auto-aggregation percentages of the C. difficile isolates and control strains. 
Ribotypes are given in parentheses. Each circle represents one of five biological repeats. The bold line represents the mean of the five biological 



































































































C. difficile strains that produced bacterial clumps at the bottom of the test tube with clear 
broth before vortexing; represented by the strong clumping of a ribotype 017 strain in Figure 
5.1 (a), had auto-aggregation percentages as high as 80%. Isolates that displayed very little 
auto-aggregation (< 15%) are represented by ribotypes 027 and 001 in Figure 5.1 (a), where 
the turbidity of the broth culture was evenly distributed and no clumping was observed. Other 
phenotypes were also observed, where only some bacterial clumping occurred (as represented 
by the ribotype 017 partial clumping in Figure 5.1 a) or the turbidity of the broth culture was 
concentrated towards the bottom of the test tube (not shown). Overall, the clinical isolates 
belonging to the ribotype 017 group (Figure 5.2 a and b) had significantly higher auto-
aggregating capacities (p = 0.011) than the non-017 isolates (Figure 5.2 c and d). Auto-
aggregation was found to be consistently highest in isolate GSH3758 (ribotype 017), and 
consistently lowest in isolate GSH4115 (ribotype 001) and the control strain 630 (ribotype 
012). A few isolates, including GSH5567 (ribotype 017), GSH5760 (ribotype 017) and 
GSH9354 (ribotype SE108), displayed a wide range of auto-aggregating percentages across 
the various replicate experiments. 
Very few published studies have investigated auto-aggregation of C. difficile, but those that 
have done so also observed different auto-aggregation phenotypes (Faulds-Pain et al., 2014; 
Purcell et al., 2012; Reynolds et al., 2011). The significantly higher auto-aggregating 
capacity of the ribotype 017 strains in the study reported in this thesis is interesting, since this 
phenotype may aid the bacterial cells during colonisation. Auto-aggregation could allow  
C. difficile to adhere to those C. difficile cells that are already attached to the host tissue, 
thereby possibly enhancing their ability to colonise the intestine. Aggregation of C. difficile is 
also important for biofilm formation, which plays a role in survival, persistence, resistance to 
antimicrobials and colonisation of the host intestine (Dawson et al., 2012; Flemming & 
Wingender, 2010). Bacterial motility, conferred by flagella, plays a role in colonisation 
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(Eaton et al., 1992; Ottemann & Lowenthal, 2002). However, according to preliminary 
analysis of the C. difficile isolates, motility did not appear to be a factor in the cell clumping 
as both motile and non-motile isolates showed strong auto-aggregation phenotypes (results 
not shown).  
The CwpV protein reportedly promotes auto-aggregation of C. difficile (Reynolds et al., 
2011). The expression of this protein is phase variable, which may explain the various auto-
aggregating phenotypes observed between the C. difficile clinical isolates, as well as variation 
within a strain in replicate experiments. 
 
5.3.4 Orientation of the inversion region upstream from the cwpV gene 
In order to investigate a possible genetic basis for the various auto-aggregating phenotypes 
observed in the clinical strains isolated in this study, the inversion region upstream of the 
cwpV gene was amplified using primers that separately targeted the ON and OFF 





Figure 5.3 Representation of the annealing sites of the primers to probe the orientation 
of the inversion region upstream of the cwpV gene. The R primer anneals outside the 
inverted repeats (LIR and RIR). The OFF-F and ON-F primers anneal inside the inversion 
region in opposite orientations. A 400 bp fragment was amplified when the inversion region 
was in the OFF orientation, and a 300 bp fragment was amplified when the sequence was 
inverted (ON orientation) (Adapted from Emerson et al., 2009). 
 
Both the ON and OFF orientations of this region were successfully amplified in all the 
clinical isolates and reference strains regardless of their differing auto-aggregating 




Figure 5.4 PCR detection of the orientation of the inversion region. A representative gel 
image showing fragments of the ON and OFF orientation of the region upstream from the 
cwpV gene amplified from GSH3758 (a highly-aggregating isolate) GSH4115 (a non-
aggregating isolate) and GSH5567 (an isolate of varying auto-aggregating capacity).  
 
500 bp  
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The PCR products of both orientations of the C. difficile 630 reference strain were sequenced 
and compared to the nucleotide sequences of the inversion region in the published C. difficile 
630 genome sequence obtained from NCBI. Nucleotide sequence alignments of both 
orientations confirmed that the correct region was amplified from the genome of the clinical 
isolates. 
A published study reported that a non-aggregating strain only had the OFF orientation of the 
inversion region and did not express CwpV due to a mutation in the region (Emerson et al., 
2009). All the non-aggregators in this current study had the ON orientation of the inversion 
region in addition to the OFF orientation. While the ON orientation was present in the non-
aggregating isolates of this current study, often the band intensity of the OFF PCR product 
appeared to be stronger than the ON PCR product (Fig 5.4). It is possible that differences in 
expression of the cwpV gene may play a role in the observed different auto-aggregation 
phenotypes. Published studies have reported that throughout the growth period only 5 – 10% 
of cells within a population express CwpV (Emerson et al., 2009; Reynolds et al., 2011). This 
percentage has been shown to increase (up to 95% of the cell population expressing the gene) 
in lysogenic C. difficile R20291 cells carrying the ΦCD38-2 prophage, possibly due to 
interference with the RecV-mediated recombination process responsible for the ON-OFF 
inversion (Sekulovic & Fortier, 2014). 
 
5.3.5 Semi-quantification of cwpV gene expression by RT-PCR 
A semi-quantitative RT-PCR pilot investigation was done to determine the approximate 
levels of transcription of the cwpV gene in strains showing different auto-aggregation 
phenotypes. Three C. difficile isolates of different auto-aggregating capacities were selected: 
GSH3758, which had the highest auto-aggregation percentage, GSH4115, which had the 
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lowest, and GSH5567, which displayed the widest range of auto-aggregating phenotypes 
(Figure 5.2). The transcription level of cwpV was evaluated semi-quantitatively by analysing 
the band intensity of the cwpV PCR product in the agarose gel image as compared with the 
corresponding 16S rRNA PCR product as an internal reference gene to normalise the values 
of the expression levels. Based on the band intensity, presented as a ratio, the highest 
expression level was observed in the high auto-aggregating strain, GSH3758, while various 
expression levels were observed among the three biological repeats of GSH5567 which was 










Figure 5.5 Semi-quantification of the cwpV gene expression by RT-PCR. (a) RT-PCR of 
the cwpV and 16S rRNA gene transcripts. The cDNA of the cwpV and 16S rRNA gene were 
amplified in a multiplex reaction. Genomic DNA of GSH3758 was used as a PCR control.  
(b) The band intensity of the cwpV PCR product as a measure of gene expression. The mean 
band intensity and standard error of the cwpV PCR product expressed as a ratio to the 16S 
rRNA PCR product. Error bars represent standard error of 3 biological replicates. 
 
The potentially varying cwpV expression levels and the varying auto-aggregating phenotypes 
displayed by GSH5567, and the uniform cwpV expression levels of GSH3758 and GSH4115, 
which both also displayed consistent auto-aggregating percentages, suggest that the 
expression level of the cwpV gene may have played a role in the observed auto-aggregation 
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phenotypes. However, RT-PCR was performed only on three C. difficile isolates as a 
preliminary investigation of cwpV expression levels and this can only be considered a pilot 
experiment since the sample set was small and the statistical significance of the differences 
between the expression levels of the various isolates could not be determined. Additionally, 
end-point RT-PCR analysis, as opposed to fully quantitative real-time PCR (qRT-PCR), is 
only able to provide an indication of major differences in the expression level of genes and 
does not take account of possible differences in the primer amplification efficiencies across 
the three strains. However, the results do warrant further investigation. Quantitation of cwpV 
expression can be improved using qRT-PCR and including validated reference genes in the 
analysis (Bakker et al., 2012; Metcalf et al., 2010). In addition, immunolabeling using 
antibodies raised to the CwpV protein could be used to visually assess the number of cells 
expressing the protein (Sekulovic & Fortier, 2014).    
The different auto-aggregation phenotypes may also be attributed to the nature of the  
C-terminal domain of the CwpV protein, which has been shown to vary across C. difficile 
strain types and to promote different auto-aggregation phenotypes (Reynolds et al., 2011). A 
published study over-expressed the CwpV protein from several C. difficile strains in a  
C. difficile 630 ΔcwpV mutant and found that they affected the ability of the strain to auto-
aggregate (Reynolds et al., 2011). The CwpV protein from the C. difficile 630 strain 
performed the best at inducing auto-aggregation, followed by the CwpV protein from a 
ribotype 027 strain, while the same protein from a ribotype 017 strain did not induce 
aggregation in the C. difficile 630 ΔcwpV mutant. In the study reported in this thesis (Figure 
5.2), the C. difficile 630 reference strain had the least auto-aggregating ability among the 
entire sample set, and the ribotype 027 reference strains also had low auto-aggregating 
percentages. Compared to these strains, the ribotype 017 strains were significantly better 
auto-aggregators. However, it should be noted that the two studies are not directly 
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comparable since slightly different assay methods were used. The auto-aggregation assay in 
the published study examined cell clumping over time in a dense suspension of cells, starting 
with an OD600nm of 10 (Reynolds et al., 2011), whereas, the current study examined clumping 
after 16 hours of growth in broth medium (Purcell et al., 2012).  
Further research investigating the genetic basis for cwpV expression and its possible role in 
auto-aggregation is necessary to support these results. Future work should include making a 
cwpV mutation in a strong auto-aggregating ribotype 017 strain and observing any 
physiological changes. Mutation using ClosTron is not an option as the strong auto-
aggregators all contained the ermB gene and are resistant to erythromycin and lincomycin, 
which are the antimicrobials used to select for intron insertion during the mutation process 
(Heap et al., 2007, 2010). However, recently developed allelic exchange-based methods can 
be used to create cwpV mutants (Ng et al., 2013). 
Additional candidate proteins or factors that are known to contribute to or regulate C. difficile 
auto-aggregation should also be investigated. These include cyclic diguanylate and flagellar 
modifications (Bordeleau et al., 2015; Faulds-Pain et al., 2014; Purcell et al., 2012). These 
were not investigated in the current study and offer alternative targets for analysis. To 
determine whether any of these proteins potentially play a role in auto-aggregation, a 
proteomics analysis can be conducted whereby the expression of these proteins during auto-
aggregation can be compared between a strong aggregating and a weak aggregating clinical 







The data reported here showed that the ribotype 017 strains were significantly better auto-
aggregators than the other ribotypes tested. The literature suggests that this may play a role in 
colonisation, and further experiments should aim at assessing whether this strong auto-
aggregation phenotype is associated with enhanced adherence to intestinal cells and/or more 
robust biofilm formation.  If this is so, the cwpV expression levels of GSH3758, GSH4115 
and GSH5567 should be fully characterised to determine whether they were in agreement 
with their auto-aggregation phenotypes. In this preliminary study, semi-quantitative RT-PCR 
of a subset of strains suggested that the expression level of cwpV may play a role in auto-
aggregation and subsequently a potential role in colonisation. Future studies should include 
determining whether mutations in or the knockout of cwpV in a strong auto-aggregating strain 
reduces its aggregation and biofilm formation ability. Alternative accurate quantitative 
methods for determining the expression level, such as qRT-PCR or immunolabeling of the 







Prior to this study, very little was known about the epidemiology or the pathogenesis of  
C. difficile strains potentially spreading and causing disease in patients attending Groote 
Schuur Hospital. At the initiation of this study, an EI-based toxin protein detection diagnostic 
method was used routinely at this hospital to detect C. difficile in stool specimens from 
diarrhoea patients. However, it was not known whether this diagnostic method was clinically 
valid. This project was designed as a pilot study to determine the most appropriate, accurate 
and sensitive method for the detection of C. difficile in the hospital setting. In addition,  
C. difficile was isolated and characterised at the molecular and phenotypic levels in order to 
gain insight into the identity, epidemiology and pathogenesis of these strains.  
C. difficile was detected by selective culture and gene-specific PCR in a significant 
proportion of symptomatic patients in the local setting.  However, the toxin detection assay 
did not successfully determine whether these isolates could produce biologically active 
toxins. In addition, the EI-based methods designed to detect the C. difficile toxins A and B in 
stool specimens were not clinically sensitive, and were, therefore, not recommended as a 
stand-alone assay in the local setting. Based on the evaluation conducted in this study, the 
Microbiology Laboratory of the NHLS at Groote Schuur Hospital adopted the GeneXpert  
C. difficile detection method as it performed the best in confirming the presence of C. difficile 
DNA. However, the limitation of the GeneXpert technique is that, although it targets some  
C. difficile toxin-encoding genes (which can indicate the presence of the organism in stool 
specimen) it cannot diagnose the patients as actively CDI-positive since it cannot detect the 
disease-causing toxin proteins themselves. Future studies could make use of CCNA or 
116 
 
ELISA to detect actual C. difficile toxin production in addition to using the GeneXpert for 
DNA detection. 
Through strain typing of the C. difficile isolates and through molecular and phenotypic 
characterisation, PCR ribotype 017 was identified as the prevalent strain among the isolates. 
C. difficile ribotype 017 strains differed significantly from the other strain types. Genotyping 
based on both MLVA and sequencing of the tcdC gene grouped the ribotype 017 strains in a 
single and separate clade from the other C. difficile isolates with a toxin profile of A-B+. The 
PCR ribotype 017 strain has reached epidemic proportions in European and Asian hospitals, 
and it is overall the most prevalent strain type in Asia (Dobreva et al., 2013; Hawkey et al., 
2013; Lee et al., 2014; Pituch et al., 2011), but is less common at other international sites 
(Cheknis et al., 2009; Tenover et al., 2011). By expanding the pilot study to other hospitals in 
Cape Town and the rest of the country, it could be determined whether the prevalence of 
ribotype 017 is the norm within the larger Cape Town area and/or South Africa as a whole. If 
this ribotype predominates in South Africa, a large cohort comparison of this strain type from 
all these hospitals could determine whether they have pathogenic characteristics in common. 
In addition, a comparison of the patient risk factors in the hospital settings could reveal why 
and how these ribotype 017 strains are predominant in these particular hospital settings. Other 
genotyping methods such as MLST or WGS could also be used in future studies to determine 
the source and/or the transmission of these ribotype 017 isolates within the local setting, as 
well as other hospitals (Cairns et al., 2015; Didelot et al., 2012; Eyre et al., 2013a, b; Walker 
et al., 2012). These two typing techniques can be used to track the accumulation of changes 
in the respective targeted regions of the genome over time, which could be used to 
reconstruct the transmission pattern of C. difficile strains. Obtaining samples from hospital 
surfaces or the hands of healthcare workers could be used to determine whether 
environmental contamination is a source and/or contributes to the transmission of CDI. A 
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recent study involved WGS analysis of ribotype 017 strains isolated from patients and the 
hospital environment (Cairns et al., 2015). Data generated was used in conjunction with 
patient and hospital information to trace which strains were transmitted between patients or 
via ward contamination, which were community-acquired or which persisted on hospital 
surfaces over a long period of time. All this information would be useful in implementing 
appropriate infection control procedures. 
The GeneXpert C. difficile detection method was developed based on the emergence of the 
hyper-virulent ribotype 027 strain in North America and Europe. With the emergence of 
ribotype 017 strains worldwide with a high prevalence in some European and Asian hospitals, 
as well as the local setting of this study, it would be more useful for epidemiological purposes 
to use a diagnostic test that could differentiate between toxinogenic A+B+ and A-B+ strains 
or presumptively detect PCR ribotype 017. While the Hain Lifescience assay evaluated in this 
study was not as sensitive as the GeneXpert, it may have value in the local setting as it targets 
both toxin A and B genes; however it also has a longer turnaround time than the GeneXpert 
leading to delays in the implementation of appropriate therapy for patients. Based on the 
molecular characterisation conducted in this study, a NAAT could additionally screen for the 
tcdA gene with the 1.8 kb deletion, the tcdC-sc7 genotype, and the various mutations in the 
gyrA and gyrB genes in order to presumptively identify ribotype 017 strains. 
Antimicrobial susceptibility profiling revealed that the ribotype 017 strains were generally 
resistant to high-levels of antimicrobials, and were often multi-drug resistant. Reduced 
susceptibility to metronidazole and resistance to moxifloxacin were characteristic of only 
ribotype 017 strains, while resistance to erythromycin, clindamycin and ciprofloxacin were 
primarily a characteristic of these strains, but was also observed in some of the other 
ribotypes. The high-level antimicrobial resistance profile may explain the high prevalence of 
ribotype 017 isolated from patients attending the Groote Schuur Hospital where these 
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antimicrobials are generally in common use for the treatment of infections (CDI and other) 
and may favour selection of these bacteria. A cohort study could be conducted in the Groote 
Schuur Hospital to investigate specifically whether certain antimicrobials, such as 
moxifloxacin, are in fact risk factors for the development of CDI in the local setting. This 
study would involve monitoring the development of CDI in symptomatic patients and 
collecting data regarding administration of antimicrobials, other treatment received or 
procedures performed, as well as their diagnosis (Pépin et al., 2005). 
The presence of the ermB gene among the erythromycin-resistant strains and the presence of 
previously characterised mutations in the gyrA and gyrB genes among the strains displaying 
some level of resistance to moxifloxacin suggest that these are the genetic determinants 
responsible for resistance to these antimicrobials. The basis for the reduced susceptibility to 
metronidazole observed amongst some ribotype 017 strains could not be determined, 
although this is likely to be a result of several contributing factors rather than a single 
underlying genetic mechanism (Chong et al., 2014; Lynch et al., 2013). 
Auto-aggregation analysis revealed that the ribotype 017 strains isolated in this study were 
significantly stronger auto-aggregators than the other ribotypes. Auto-aggregation may be 
important for biofilm formation, which plays a role in colonisation. Future studies could 
involve an adherence assay to determine whether the strong auto-aggregating strains are also 
more efficient in forming biofilms in vitro on abiotic surfaces (Dawson et al., 2012). This 
increased auto-aggregation capacity may enable the ribotype 017 strains to out-compete other 
ribotypes in the colonisation process. To investigate this, a gut model could be infected with a 
strong auto-aggregating strain and a non-aggregating strain (Baines et al., 2013; Crowther et 
al., 2014).  
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The study reported in this thesis was not able to determine whether cwpV and its expression 
level, as determined by semi-quantitative RT-PCR, contributed to the auto-aggregation 
capacity. In future studies, quantitative RT-PCR (qRT-PCR) or immunolabelling of the 
CwpV protein could be used to determine the mRNA and protein expression level of cwpV, 
respectively. In addition, mutation of cwpV in a strong auto-aggregating strain, using a gene 
specific insertion or deletion strategy, could be used to determine whether CwpV contributes 
towards the strong auto-aggregation phenotype of the ribotype 017 strains in this study 
(Chapter 5). C. difficile ΔcwpV mutants could also be compared to wild-type strong auto-
aggregators in the adherence assay, or co-infected in the gut model. 
In summary, this pilot study successfully identified and investigated the presence of  
C. difficile in approximately 20% of symptomatic patients at Groote Schuur Hospital. It 
provided data on the most appropriate diagnostic method that could be used to detect its 
presence, information on the strain types potentially causing disease, and their antimicrobial 
resistance and auto-aggregation phenotypes. Hypotheses were also developed which 
suggested how various strain types, primarily ribotype 017, were able to persist and spread in 
the hospital, and identified a candidate gene, which may be involved in pathogenesis, for 
future study. The results produced by this study provide a platform for future studies to gain a 
better understanding of the C. difficile strains causing disease in South Africa. This would 
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